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The versatile biomedical applications of bismuth-
based nanoparticles and composites: therapeutic,
diagnostic, biosensing, and
regenerative properties
Mohammad-Ali Shahbazi, *ab Leila Faghfouri,b Mo´nica P. A. Ferreira,a
Patrı´cia Figueiredo,a Hajar Maleki, c Farshid Sefat,de Jouni Hirvonena and
He´lder A. Santos *af
Studies of nanosized forms of bismuth (Bi)-containing materials have recently expanded from optical,
chemical, electronic, and engineering fields towards biomedicine, as a result of their safety, cost-effective
fabrication processes, large surface area, high stability, and high versatility in terms of shape, size, and
porosity. Bi, as a nontoxic and inexpensive diamagnetic heavy metal, has been used for the fabrication of
various nanoparticles (NPs) with unique structural, physicochemical, and compositional features to
combine various properties, such as a favourably high X-ray attenuation coefficient and near-infrared (NIR)
absorbance, excellent light-to-heat conversion efficiency, and a long circulation half-life. These features
have rendered bismuth-containing nanoparticles (BiNPs) with desirable performance for combined cancer
therapy, photothermal and radiation therapy (RT), multimodal imaging, theranostics, drug delivery,
biosensing, and tissue engineering. Bismuth oxyhalides (BiOx, where X is Cl, Br or I) and bismuth
chalcogenides, including bismuth oxide, bismuth sulfide, bismuth selenide, and bismuth telluride, have
been heavily investigated for therapeutic purposes. The pharmacokinetics of these BiNPs can be easily
improved via the facile modification of their surfaces with biocompatible polymers and proteins, resulting
in enhanced colloidal stability, extended blood circulation, and reduced toxicity. Desirable antibacterial
effects, bone regeneration potential, and tumor growth suppression under NIR laser radiation are the main
biomedical research areas involving BiNPs that have opened up a new paradigm for their future clinical
translation. This review emphasizes the synthesis and state-of-the-art progress related to the biomedical
applications of BiNPs with different structures, sizes, and compositions. Furthermore, a comprehensive
discussion focusing on challenges and future opportunities is presented.
1. Introduction
Given the importance of human life, scientists have always
sought to promote the conventional treatment methodologies
and diagnosis approaches of various diseases. Despite many
attempts, unresolved challenges have still remained for hard-
to-treat diseases, including cancer, resistant bacterial infec-
tions, heart diseases, as well as organ dysfunction disorders,
resulting in a high annual mortality rate.1–6 As a solution,
nanoscience researchers are always looking for efficient parti-
cles that can lead to the development of new medicines to assist
in early diagnosis and the therapy of life-threatening diseases.7
There are plenty of organic and inorganic nanocarriers under
investigation for such purposes.8–17 Among them, bismuth-
containing nanoparticles (BiNPs), although in their infancy,
have recently garnered much attention as a research break-
through for biomedical applications, owing to their excellent
properties, which include high stability, high surface area, strong
diamagnetism, high electrical and magnetoresistance when
placed in a magnetic field, desirable catalytic activity, ease of
functionalization, cost-effectiveness, chemical inertness, low toxi-
city, high X-ray attenuation coefficient, strong near-infrared (NIR)
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absorbance, high photothermal-conversion efficiency, and
favorable antibacterial activity.18–20 Moreover, Bi is considered
as one of the least toxic and biologically non-reactive heavy
metals, which is more suitable for in vivo applications com-
pared to other metals such as silver.12 The ease in controlling
their particle size and shape during synthesis is another
advantage of BiNPs, which can open new opportunities for its
future clinical applications.21 All of the abovementioned bene-
fits contribute to the increasing interest in the biomedical
applications of BiNPs over other metal-based NPs.
While Bi has been conventionally used in the production of
pharmaceutical products for the treatment of gastrointestinal
disorders, hypertension, and syphilis, its usage in nanostruc-
tural forms has been widely expanded in recent years in various
domains, such as X-ray radiotherapy (RT), biosensors, heavy-
metal ion detectors, antimicrobial formulations, combined
cancer therapy, bioimaging, and tissue engineering (Fig. 1).22–25
For these applications, single-component NPs of Bi can be used as
intermediates to fabricate other types of BiNPs, including Bi
oxyhalides (BiOX, where X is Cl, Br or I) and Bi chalcogenides
(e.g., Bi oxide (Bi2O3), Bi sulfide (Bi2S3), Bi selenide (Bi2Se3), and Bi
telluride (Bi2Te3)). The nanostructures of such Bi-based compounds
may adopt different morphologies, such as nanotubes, nanowires,
nanorods, nanoflowers, nanoneedles, nanoflakes, nanoplates,
nanosheets, and nanooctahedra. Other types of multi-component
Bi nanostructures have also been fabricated and used for bio-
medical applications, including Bi ferrite (BiFeO3), Bi tungstate
(Bi2WO6), Bi molybdate (Bi2MoO6), Bi vanadate (BiVO4), Bi
phosphate (BiPO4), Bi oxide carbonate ((Bi2O)2CO3), and Bi
dimercaptopropanol (BisBAL). The methods developed for the
synthesis of these NPs include hydrothermal or solvothermal
syntheses, evaporation methods, sol–gel approaches, micro-
emulsion techniques, chemical synthesis, microwave irradiation,
sonochemical synthesis, and laser-mediated approaches.26–32
In biomedicine, one of the main research areas of BiNPs is
cancer therapy. While common therapies employed for cancer,
including surgery, chemotherapy and RT, have constantly
advanced over the decades, this disease is still one of the
leading causes of human death and intensive side effects of
the conventional monotherapies have remained unresolved.33–35
BiNPs have stimulated an upsurge in interest within the area of
synergistic cancer therapy due to their remarkable absorbance of
NIR light, high light-to-heat conversion efficiency, and excellent
photothermal stability, meaning that they can be used for
photothermal therapy (PTT) in combination with chemotherapy,
radiotherapy, and immunotherapy.36–38 RT of cancer is also
possible using BiNPs as a potential radiosensitizer, with better
performance compared to gold (Au) and germanium (Ge) NPs.
High-intensity focused ultrasound (HIFU) therapy of cancer
using BiNPs has also been reported.39 Nevertheless, the lack of
early diagnosis might hinder the efficient killing of cancer cells
by such NPs. Therefore, there has been exponential growth in
the use of BiNPs as excellent contrast agents for the early
diagnosis of cancer through different imaging modalities, such
as computerized tomography (CT)-scan examinations and photo-
acoustic (PA) imaging at a very low dose, allowing more flexibility
in a clinical setting.40–43 In addition, BiNP-mediated infrared
thermography (IRT) can also be employed as an imaging method
to monitor tumor temperature variations during PTT. The
suitability of Bi for CT-imaging is due to its high K-edge value
(K-edge value = 90.5 keV) and large X-ray attenuation coefficient
(5.74 cm2 g1 at 100 keV), which is greater than those of other
high-Z materials.44 Its appropriate PA and IRT imaging resolu-
tions are also due to its desirable photothermal conversion
efficiency in the NIR window.43 Moreover, some researchers
have greatly broadened the application of BiNPs by integrating
new functional components into their structure, paving the way
for new applications of BiNPs. For example, the integration of
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manganese (Mn), iron (Fe), and gadolinium (Gd) with BiNPs
has resulted in the NPs becoming a contrast agent for MRI.45–48
The imaging potential of BiNPs can be combined with its
PTT effect and other therapeutic approaches, such as immuno-
therapy and chemotherapy, to develop theranostic Bi-based
medicines that satisfy strict demands for multimodal imaging-
guided synergistic therapies and overcome the deficiencies
of single imaging methods and monotherapy of cancer.49
Promising outcomes using theranostic BiNPs have been
obtained for thermo-chemotherapy,50,51 chemo-radiotherapy,52
thermo-radiotherapy,53,54 and radio-immunotherapy55 with
significantly higher inhibition of cancer cells, compared to
available monotherapies. In biosensing applications, BiNPs have
also opened up a new gateway as promising materials to
fabricate biologically compatible devices for the rapid and easy
detection of biological events. For example, Bi2WO6 NPs with
multilayer reduced graphene nanosheets as a modified electrode
have been reported for the rapid electrochemical sensing of
oxidative stress in biological samples.56
In this review, we will provide a comprehensive overview
of the recently generated information on the synthesis, bio-
distribution, safety, as well as modifications conducted on
various types of BiNPs to produce multifunctional materials
for different biomedical applications that have caught the
interest of the scientific community. The available literature
suggests that biomedical research on BiNPs has been exten-
sively growing and various nanoforms of Bi with different
compositions have been exploited for biological applications,
including drug delivery, antimicrobial activity, bioimaging,
cancer therapy, biosensing, and tissue engineering. Nevertheless,
to the best of our knowledge, there has been no comprehensive
review on such features of BiNPs. Therefore, we will discuss all
representative studies exploiting BiNPs for the abovementioned
biomedical applications. Future perspectives in the development
of these NPs for biomedical applications are also proposed.
2. Principles and innovations in the
synthesis of BiNPs
BiNPs have attracted increased attention for biomedical
applications due to their low toxicity and environmentally
friendly properties.57 Moreover, the relatively low price and
abundancy of Bi is attractive for its large-scale applications.58
Bulk Bi is a semimetal with large Fermi wavelengths, high
magnetoresistance, and strong diamagnetism,59 which can be
used to fabricate BiNPs with different shapes and composi-
tions. The most common ones are Bi2O3, Bi2S3, Bi2Se3, and
Bi2Te3 that belong to the group VI of Bi compounds, so-called
Bi chalcogenides. The nanostructures of Bi chalcogenides
exhibit intrinsic electronic and optical properties, which make
them suitable for a wide range of biomedical applications;60
however, these properties are influenced by their morphology
and crystal structure.61 Bi oxyhalides (BiOX, where X is Cl,
Br, or I) are another class of Bi compounds that belong to the
V–VI–VII ternary oxide semiconductor materials. Due to their
Fig. 1 A schematic overview of the emerging biomedical applications of BiNPs. The main biomedical applications include drug delivery and cancer
therapy, bioimaging, the development of theranostic NPs, antibacterial uses, regenerative medicine (particularly bone engineering), and the fabrication
of biosensors.
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layered structure and high chemical stability, along with their
optical, electrical, and mechanical properties, these types of
materials have mainly attracted increased attention for photo-
catalytic activities under visible light irradiation, as well as
electronics, and energy storage.58,62–64 Other types of Bi nano-
structures have also been fabricated, including BiFeO3, Bi2WO6,
Bi2MoO6, BiVO4, BiPO4, (Bi2O)2CO3, and BisBAL.
24,65–70 The
main characteristics, properties, and applications of the most
common types of BiNPs are summarized in Table 1.
Through the adjustment of various parameters during the
fabrication process, Bi nanostructures with different morphol-
ogies can be prepared, including: (i) 0D nanostructures, such as
nanospheres, and nanocubes; (ii) 1D nanostructures, including
nanowires, nanorods, and nanotubes; and (iii) 2D nanostructures,
such as nanoplates, nanosheets, and thin films.111 Increased efforts
have been made to fabricate the above morphologies of
BiNPs using different methodologies, such as hydrothermal
or solvothermal synthesis, evaporation methods, sol–gel
approaches, microemulsion techniques, chemical synthesis,
microwave irradiation, sonochemical synthesis, and laser-
mediated approaches.65,112–119 In this section, the most com-
mon approaches introduced for the fabrication of BiNPs will be
discussed, and the principals of each technique will be
detailed, along with the influence of the different synthesis
parameters on the morphology of the Bi nanostructures, and
consequently, on their properties. The different fabrication
methods of the main BiNPs, the treatment conditions applied
to prepare these structures, and their size, shape, properties
and possible applications are summarized in Table 2.
2.1. Hydrothermal/solvothermal/ionothermal synthesis of
BiNPs
Hydrothermal synthesis of NPs has been employed for the
fabrication of different inorganic materials, such as BiNPs.
Generally, hydrothermal synthesis involves crystal growth in
aqueous solutions under high temperatures (not more than
300 1C) and high pressure, in which the substances are not
soluble at normal temperatures and pressures (100 1C,o1 atm).164
The reaction is usually conducted in a metallic sealed reactor, a
so-called autoclave, made of Teflon and coated with platinum,
gold, or silver to protect the reactor from highly corrosive
solvents.165 The hydrothermal process presents energy saving
and cost-effective benefits in fabricating BiNPs, with controllable
particle size, morphology and degree of crystallinity by changing
the concentration of the Bi source.125 Furthermore, the proces-
sing temperature and reaction time can be lowered using a
microwave-assisted hydrothermal approach, allowing uniform
nucleation of the powders in suspension.166 Additionally, by
controlling the temperature, reaction time, and the pH value
of the solution, the morphologies of the BiNPs can be tuned. For
example, Deng et al.141 showed that applying a lower tempera-
ture and shorter reaction time favored the formation of nano-
tubes of Bi-oxyhalide NPs, while higher temperatures and longer
reaction times led to the formation of more stable Bi oxyhalide
NPs with nanobelt or nanoflake-like shapes. Additionally, higher
temperatures for the hydrothermal reaction usually favor the
preparation of uniform Bi structures, which can be ascribed to
the increased crystal growth rate at a higher temperature.158 In
another study, Cui et al.150 demonstrated that the size, shape
and photocatalytic activity of Bi2WO6 NPs are highly dependent
on the pH value (NaOH content) of the initial synthesis solution
(Fig. 2). At pH 1–4, the particles exhibited flower-like hierarchical
microspheres in which the size constantly decreased when the
pH value increased (the particle size was 7 mm at pH 1 and
1.5 mm at pH 4). When the pH values were increased further
from 5 to 9, the Bi2WO6 particles showed irregular flake-like
structures; and at pH 10–11, the prepared Bi2WO6 NPs presented
a uniform sphere-like morphology with an average size of 85 nm.
The flower-like microspheres prepared at pH 3 presented the
highest photocatalytic activity, with 99% degradation after 2 h
of irradiation.
During hydrothermal synthesis, the size of the prepared
particles depends on the competition between crystal nuclea-
tion and crystal growth, i.e., the crystal size is small when the
rate of crystal nucleation is higher than that of the crystal
growth.167 In order to control the growth speed of the prepared
crystals, Wang et al.145 prepared BiFeO3 via a polymer-assisted
hydrothermal process, in which poly(vinyl alcohol) (PVA) was
added to prevent the crystals from growing to the micrometer
size. The polymer might attach to the surface of the BiFeO3
nuclei, lowering the surface energy and the growth speed of the
BiFeO3 nuclei, and therefore, restraining the size of the resulting
particles to the nanometer range (10 nm). The addition of
different surfactants can also affect the shape of the prepared
nanostructures. For example, Dharmaiah et al.137 fabricated three
different Bi2Te3 nanostructures, using ethylene glycol (EG),
poly(vinyl pyrrolidone) (PVP), and ethylenediaminetetraacetic acid
(EDTA) as surfactants, in order to obtain nanospheres (25 nm),
nanoplates (200 nm) and nanoflakes (300 nm), respectively. These
results suggested that surfactants can act as morphology-directing
agents, regulating the crystal growth to form nanostructures with
several morphologies, and subsequently affecting the physico-
chemical properties of the particles.
Solvothermal synthesis uses similar conditions to the hydro-
thermal synthesis process, but organic solvents, including
toluene, decalin and, octadecene, are used instead of aqueous
solutions. Similar to the hydrothermal process, the size and
shape of the nanocrystals can be tuned by controlling the
temperature of the reaction, and the concentration of the
Bi precursors.168 Ionothermal synthesis implicates the use of
ionic liquids as alternative solvent media to fabricate BiNPs.168
The main advantage of ionic liquids compared to traditional
organic solvents is the low interfacial tension that leads to a
high nucleation rate, and therefore, the production of very
small particles.169 As demonstrated by Wang et al., the size
and aspect ratio of the Bi2S3 nanostructures (nanoflowers to
nanorods) can be tailored by controlling the reaction time of
the thermal treatment of bismuth di-n-octyl-dithiophosphate
(Bi[S2P(OC8H17)2]3) in C16MIMBF4 as an ionic liquid solvent, at
165 1C (Fig. 3).134 Furthermore, by changing the reaction
temperature, Ma et al. fabricated BiOCl nanostructures with
different morphologies after mixing bismuth nitrate pentahydrate
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[Bi(NO3)35H2O] and [C16Mim]Cl as an ionic solvent for 12 h.142
When the temperature was maintained at 200 1C, curved
nanoplates with an average thickness of around 14 nm where
obtained, which were thinner than the nanoplates produced at
180 1C. Furthermore, nanoplate arrays were obtained when
a lower reaction temperature (120 1C) was used, where the
thickness of the nanoplates was ca. 32 nm.
2.2. Sol–gel synthesis approaches in fabricating bismuth
nanostructures
The sol–gel method is one of the most common chemical
synthesis methods used to fabricate sub-micron metal oxide
particles with narrow particle size distributions.65,168 This
method offers good homogeneity and morphological control,
lower processing temperature compared to other methods, high
purity, and easy preparation of thin films and coatings.168 Using
different approaches for the treatment of the sol–gel precursor,
such as spin-coating, template deposition, electrospinning or
heating, it is possible to obtain NPs with different morphologies,
including thin films, nanotubes or nanowires, nanofibers, and
spherical NPs, respectively (Fig. 4).65,116,170,171 Generally, all
these approaches consist of two phases: (i) the solution phase,
made up of a colloidal suspension of solid particles, and (ii) the
gelation phase, where an interconnected network of solid-phase
particles is formed.172 The fabrication process of the Bi nano-
structures via the sol–gel method is initiated using a chemical
solution that acts as the precursor, made up of a metal source,
solvent and chelating agent. The process can be manipulated by
changing different parameters, including the initial precursors,
nature of the solvent, gelation time and conditions (e.g., tempera-
ture and pH), types of additives (e.g., catalysts, surfactants and
morphology directing agents), and degree of solvation.65,172,173
BiFeO3 nanostructures are commonly fabricated using the
sol–gel method, where the initial precursor solution includes
metal nitrates, such as Bi(NO3)35H2O and Fe(NO3)39H2O, and
an organic solvent (e.g., 2-methoxyethanol (2-MOE) or EG) that
replace the water-based solvents, since metal nitrates present
good solubility in these solvents.65,174 Gao et al.174 used Bi(NO3)3
5H2O and Fe(NO3)39H2O as starting materials and EG as a
solvent, without the presence of other surfactants, in order to
evaluate the effect of the calcination temperature and concen-
tration of the precursor solution on the particle size of BiFeO3
prepared via a simple sol–gel method. Precursor solutions at
concentrations of 0.3, 0.4, and 0.5 mol L1 were stirred during
1.5 h at 80 1C to form gels, which were then kept at 120 1C for
4 days to obtain xerogels. Afterwards, the xerogel powders were
pre-treated at 300 1C for 4 h, before calcination treatment at 500,
550 and 600 1C for 2 h. The size of the prepared particles ranged
between 50 and 250 nm, which increased with the concentration
of the precursor solution, due to their aggregation into bigger
particles at a higher concentration of the precursor solution.
An increase in the annealing temperature also translated into an
increase in the particle size. Additionally, they found that a
higher visible-light response, due to a smaller band gap, seemed
to be the main factor for superior photocatalytic efficiency when
the BiFeO3 particles were similar in size.T
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During the sol–gel synthesis of the BiNPs, the addition of
chelating agents, such as acetic anhydride, acetic acid, citric
acid, or tartaric acid, can determine the morphology and purity
of the final product. Therefore, selection of the appropriated
chelating agent is essential for the successful preparation of
Bi nanostructures.65,175 Wang et al. synthesized pure BiFeO3
using a tartaric acid-assisted sol–gel method, with a particle
size ranging from 60 to 90 nm and polyhedral morphology.175
After mixing Bi(NO3)35H2O and Fe(NO3)39H2O in dilute nitric
acid, the tartaric acid in EG was successively added to the
previous solution under stirring, and the resulting solution was
kept at 140 1C until a dried gel was obtained. The gel was pre-
treated at 400 1C to remove organic compounds and NO3
, and
then calcinated at 500 1C for 1 h. After this process, pure BiFeO3
was obtained due to the formation of stable heterometallic
polynuclear complex bonds between the metal ions and the
tartaric acid. However, when citric acid was used as a chelating
agent instead of tartaric acid, Bi2Fe4O9 and Bi25FeO40 impu-
rities were observed, which can be attributed to the dimeric
nature of the citrate complex.
Originally developed in the 1960s, the Pechini method is
another common sol–gel synthesis technique used to prepare
layered oxide perovskites, based on an esterification reaction
between a carboxylic acid and an alcohol.176 Hasan et al. used a
modified Pechini method to obtain BiFeO3 NPs with different
morphologies through alteration of the annealing temperature.148
Bi(NO3)35H2O and Fe(NO3)39H2O were dissolved in water, citric
acid was added as a chelating agent to complex the metal cations,
and the solution was then stirred and heated at 70–75 1C for 3 h.
After that, EG was added as a polymerization agent, and the
resultant solution was heated at 85–90 1C to initiate the polymer-
ization reaction until a gel was formed. After drying the gel, the
precursor xerogel was powdered and annealed at temperatures
ranging from 400 to 800 1C for 2 h to obtain BiFeO3 NPs with
Fig. 2 The effects of pH on the morphology and size of Bi2WO6 particles. Scanning electron microscope (SEM) images of Bi2WO6 particles prepared at:
(a) pH 1; (b) pH 2; (c) pH 3; (d) pH 4; (e) pH 5; (f) pH 7; (g) pH 8; (h) pH 9; (i) pH 10, and (j) pH 11. Adapted with permission from ref. 150, Copyright 2016.
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Fig. 3 Transmission electron microscope (TEM) images of Bi2S3 nanostructures prepared after (a) 3 s, (b) 5 s, (c) 5 min, (d) 30 min, (e) 1 h, and (f) 5 h of
reaction time. Adapted with permission from ref. 134, Copyright 2010.
Fig. 4 A schematic diagram of the available sol–gel mediated approaches used for the fabrication of Bi-containing nanostructures.
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average sizes of 21–68 nm. Spherical NPs were obtained when the
powders were annealed up to 600 1C, while stable cubic NPs were
produced at an annealing temperature of 800 1C.
As mentioned earlier, the sol–gel method can be combined
with the electrospinning technique to obtain BiFeO3 nano-
fibers, as reported by Wang et al.177 For this purpose, the initial
precursors Bi(NO3)35H2O and Fe(NO3)39H2O were dissolved in
2-methoxyethanol, and then glacial acetic acid and ethanol-
amine were added to adjust the viscosity and pH-value of the
solution under stirring. This solution was further mixed with
PVP in dimethylformamide/acetone (2 : 1 v/v). Afterwards, this
precursor solution was loaded into a plastic syringe for the
electrospinning process, using a direct current voltage of 13 kV.
The collector (aluminum foil) was attached to the cathode,
and the distance between the needle tip and the collector was
10 cm. After evaporation of the solvent, a fibrous mat was
formed on the collector, and the composite nanofibers were
dried at 60 1C for 24 h, followed by heating at 350 1C for 30 min.
Finally, thermal annealing was conducted under an argon (Ar)
atmosphere at 550 1C for 2 h to allow the production of fibers
with a rhombohedral distorted perovskite structure. These
nanofibers, with a diameter of 220–480 nm, exhibited good
magnetic response, which was ascribed to the nanometer size
of the fibers, along with photocatalytic activity under ultraviolet
(UV) and visible light irradiation.
2.3. Microemulsion technique
The microemulsion technique has attracted considerable atten-
tion in preparing colloidal metal nanostructures, due to the
ability to control the different particle properties, such as
size, geometry, morphology, homogeneity and surface area.178
Typically, in this technique, nanosized aqueous droplets are
embedded with a surfactant, distributed in an organic phase
(oil). The water phase of the microemulsion contains metal
salts and acts as a nanoreactor for the synthesis of the particles,
in which the shape and size of the particles can be tuned by
adjusting the water : surfactant ratio.117,179 The microemulsion
method allows the simultaneous synthesis and stabilization of
NPs, in which the water nanodroplets limit the particle growth,
and the presence of surfactants adsorbed on the particle
surface reduces the surface tension and the possibility of
agglomeration. The formation protocol of the BiOI–TiO2 nano-
composite is schematically shown in Fig. 5a as a general
microemulsion method to prepare BiNPs.180 The surfactant
and co-surfactant can be chosen according to the nature of
both the oil and water phases. By changing different para-
meters, such as the concentration of the different constituents
and the nature of the dispersing phase in the microemulsion
system, it is possible to control the particle morphology
and size, and consequently, their properties and application.
Nevertheless, the absence of a capping agent makes the NPs
susceptible to agglomeration as well as surface oxidation,
which is disadvantageous from materials handling and safety
viewpoints. To cope with this drawback, Purkayastha et al.117
introduced a method using thioglycolic acid to cap Bi2Te2 NPs
using a microemulsion method (Fig. 5b). Two separate micro-
emulsions were first formed from bis(2-ethylhexyl)sulfosuccinate
(AOT)/isooctane mixtures, one containing orthotelluric acid and
the second containing Bi chloride. Thioglycolic acid was then
added to a bismuth chloride/AOT/isooctane solution to convert
the transparent Bi chloride/AOT/isooctane solution into a yellow
solution as a result of the Bi ionically bonding with the
thioglycolic acid. Then, mixing of the two microemulsions
was followed by adding hydrazine monohydrate to reduce the
solution and form molecularly capped Bi2Te2 NPs, with size
diameters ranging from 2.5 to 10 nm.
2.4. Chemical approaches
Different chemicalmethodologies, including the chemical reduction
method, as well as electrochemical and photochemical approaches,
Fig. 5 (a) A flow chart showing the synthesis procedure of BiOI–TiO2 particles via the microemulsion method. Adapted with permission from ref. 180,
Copyright 2014. (b) The formation of Bi2Te2 NPs in water nanodroplets confined by bis(2-ethylhexyl)sulfosuccinate (AOT; black wiggles) in an isooctane
solution. The microemulsion containing Bi ions (red dots) ligated with thioglycolic acid (blue squiggles) was mixed with another microemulsion
containing orthotelluric acid (brown dots). The mixture was reduced using hydrazine monohydrate to produce thioglycolic acid capped Bi2Te2 NPs
(brown spheres). Adapted and reprinted with permission from ref. 117, Copyright 2006.
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can be used to synthesize a variety of Bi structures.181–183 The polyol
process is a soft chemical reduction technique used to fabricate
a large variety of metallic NPs, presenting many advantages
such as low cost, ease of use and facile scale-up. Polyols are
diol, mainly 1,2-diols, such as ethylene glycol and its deriva-
tives, including di-, tri-, tetra- and so on up to poly(ethylene
glycol). The presence of several OH groups in polyols confers
them with interesting properties, such as reduction and
coordination capabilities, which contribute desirably to the
synthesis of metal NPs. Typically, the polyol-mediated synthesis
of metallic particles involves three main steps, including:
(1) dissolving the metal precursor in an appropriate solvent,
(2) reduction and nucleation of the monomer species, and
(3) the growth and self-assembly of the nuclei/clusters to form
metal particles. The reduction conditions are a very crucial step
for controlling the size and morphology of the BiNPs during
the polyol process, subsequently enabling the tailoring of the
electronic, magnetic, optical, and catalytic properties of the
NPs.184 For example, Wang et al.181 were able to control the size
and shape of BiNPs using the polyol process (in the presence of
ethylene glycol) by changing the ratio of Bi cations (NaBiO3 as
the source) to the capping polymer, PVP, at 200 1C. As shown in
Fig. 6, different sizes andmorphologies of BiNPs were obtained by
changing the PVP :Bi molar ratio. PVP acts as a shape controlling
agent for the formation of Bi nanocubes and triangular nano-
plates, and also as a stabilizing agent to prevent the Bi spherical
particles from aggregating and forming big particles. Moreover, it
was found that the addition of Fe3+ can reduce the nucleation rate
of Bi NPs, allowing the NPs to align in the same direction and
connect to each other to form wire-like structures.181
Strong reducing agents, such as alcohols, citrate ions, hydrazine
or sodium borohydride (NaBH4) have also been reported for the
synthesis of BiNPs.184 Brown and Goforth120 synthesized BiNPs by
reducing Bi(NO3)35H2O in the presence of NaBH4, in a glycine and
dextran containing solution at pH 9. Upon the addition of the
reducing agent, the solution changed from a colorless to a black
solution in a few minutes. The dextran was used as a surfactant to
render high stability to BiNPs in aqueous solutions. The preparation
of BiNPs in 1,2-propanediol, using a borane reducing agent, and
glucose as a biocompatible surface stabilizer, has also been demon-
strated by the same team.121 Borane was selected as a reducing agent
due to its kinetically slower reactivity compared to NaBH4, providing
better size and morphology control during the formation of BiNPs,
and easy purification of the prepared BiNPs. The fraction of Bi atoms
constituted ca. 4% of the particle volume (B100000 Bi atoms/NP)
when the former method was used, while in the latter one, the
BiNPs made up around 64% of the total NP volume, containing
ca. 6 million Bi atoms per NP (Fig. 7). This higher Bi payload
resulted in a substantial improvement in the sensitivity of the
nanoplatform as an X-ray contrast agent for CT imaging.121
In addition to the above chemical approach, electrochemical
and electrodeposition methods have been applied to fabricate
BiNPs with differentmorphologies and Bi-containing films.182,185–187
Photochemical methodology is another convenient and environ-
mentally friendly chemical approach suggested for the fabrica-
tion of BiNPs. For example, Zhao et al. reported the synthesis
of Bi2S3 nanoflowers on an alumina template using a photo-
deposition technique.188 Bi(NO3)3 was used as a Bi source, and
mixed with thioacetamide as a source of S2, due to the ability
of thioacetamide to decompose under UV irradiation and
release S2, in the presence of the complex agent nitrilotriacetic
acid. Afterwards, an alumina template with pores of 100 nm
in diameter was immersed in the previous solution, and the
resulting solution was irradiated under UV light for 4 h, using a
500 W high-pressure mercury lamp (l4 290 nm) as the source
of UV irradiation. The presumed growth mechanisms of Bi2S3
nanoflowers can be described as follows: (1) the solution was
permeated through the pores of the alumina template, and the
deposition was performed in the presence of UV light until the
pores were totally filled; and (2) the formation of Bi2S3 nano-
wires in the pores occurred, and the nanowires extended to
the surface of the alumina template, and continued to grow
until Bi2S3 nanoflowers were formed. During this process, the
irradiation time and pH of the solution were found to affect the
Fig. 6 (a) A schematic diagram of the polyol process for the synthesis of BiNPs and (b) representative TEM images of: (1) single-crystalline Bi nanocubes,
prepared with a PVP : Bi molar ratio of 1.6 (scale bar = 50 nm); (2) Bi triangular nanoplates, when the molar ratio of PVP : Bi was reduced to 0.8 (scale bar =
200 nm); (3) Bi nanospheres, after increasing the molar ratio of PVP : Bi to 5 (scale bar = 50 nm); and (4) Bi nanobelts, prepared with a of PVP : Bi molar
ratio of 1.6 in the presence of Fe3+ species (scale bar = 500 nm). Adapted with permission from ref. 181, the American Chemical Society, Copyright 2006.
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morphology of the prepared Bi2S3. When the reaction time was
lower than 1 h, the decomposition reaction of the Bi–S did not
occur and Bi2S3 was not formed. Moreover, a reaction time of
4 h was required to form nanoflowers on the alumina template,
after a complete filling of the alumina template. Additionally,
the pH of the solution was found to affect the formation of the
Bi2S3 nanoflowers.
2.5. Microwave irradiation method
The microwave irradiation synthesis has been employed in the
fabrication of different inorganic materials, including BiNPs,
because it is generally quite simple, with a short reaction time,
and very energy efficient, compared to the abovementioned
methods.189 Additionally, this green synthesis method allows the
production of high purity particles with different morphologies,
with a small average size and narrow size distribution.65,190 For
example, Liao et al.190 fabricated Bi2S3 nanorods after reacting
an aqueous formaldehyde solution, containing Bi(NO3)35H2O
and thiourea, in a microwave refluxing system for 20 min,
obtaining nanorods with a diameter of around 10 nm and a
length of up to 300 nm. Formaldehyde solution was selected as a
solvent, because it led to the formation of pure and uniform
nanorods. Water and ethanol were also tested as solvents,
resulting in the formation of aggregated short rods. Additionally,
the formation of uniform and small-sized nanorods occurred
when thiourea was used as a source of sulfur. When thioacet-
amide was employed as the sulfur source, the prepared Bi2S3
nanorods were found to be thicker and longer (average diameter
of 50 nm and length up to 1–2 mm).
In the microwave irradiationmethod, ionic liquids are excellent
media for absorbing microwaves, leading to a fast heating rate.
It was demonstrated that when the ionic liquid 1-n-butyl-3-
methylimidazolium tetrafluoroborate ([BMIM]BF4) was used as
a solvent in the microwave irradiation process, the formation
of pure hexagonal-shaped Bi2Se3 nanosheets was favored.
131
However, when EG was used as the solvent in the absence
of [BMIM]BF4, irregular-shaped nanosheets were obtained,
suggesting that the presence of the ionic liquid influences the
morphology of the BiNPs. Therefore, changing the solvent and
manipulating the ratio of the solvent Bi source is very crucial
in the optimization of the microwave irradiation mediated
synthesis of BiNPs. In this context, Li et al.32 were able to
fabricate different BiPO4 nanostructures (Fig. 8), which exhibited
Fig. 7 A schematic comparison of the two BiNP formulations prepared by Brown et al. after the chemical reduction of Bi(NO3)35H2O. Reprinted with
permission from ref. 121, the American Chemical Society, Copyright 2014.
Fig. 8 SEM images of the different BiPO4 nanostructures fabricated using
the following solvents with different viscosities: (a) glycerol/water (ratio
1 : 6); (b) glycerol/water (ratio 1 : 9); (c) EG/water (ratio 2 : 1); (d) EG/water
(ratio 1 : 6); (e) diethylene glycol; and (f) 0.6 M mannitol. Reprinted with
permission from ref. 32, the American Chemical Society, Copyright 2011.
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morphology-dependent photocatalytic behavior. For that,
Bi(NO3)35H2O was dissolved with different solvent combina-
tions, such as glycerol/water or EG/water in different ratios,
pure diethylene glycol, or 0.6 M mannitol, and then mixed with
NaH2PO42H2O. The resulting mixture was further heated using
an 800 W microwave reactor for 15 min, under continuous
and vigorous stirring. The viscosity of the solvents played an
important role in the morphology and size of the BiPO4 nano-
structures, in which high viscosity of the pure diethylene glycol,
for example, favored the formation of BiPO4 NPs (Fig. 8e),
while low viscosity of the EG/water mixtures was crucial for
the formation of 1D BiPO4 nanostructures, such as short
nanorods or rice-like NPs (Fig. 8c and d).
2.6. Sonochemical- and laser-mediated approaches for the
synthesis of BiNPs
The application of high-intensity ultrasound is another facile
and versatile method that can be applied for the fabrication
of several types of nanostructured materials.191 Generally, the
so-called sonochemical approach takes advantage of the extreme
conditions induced by ultrasound, which creates unique hot
spots that are high in temperature and pressure (45000 K, and
41000 atm), and the cooling rate is over 1010 K s1 when these
bubbles implode.192,193 This technique relies on two physical
phenomena associated with ultrasound: (1) acoustic cavitation,
which involves the formation, growth and implosive collapse of
bubbles in liquid; and (2) nebulization, which involves the
creation of mist from ultrasound passing through a liquid
and impinging on a liquid–gas interface, being the basis for
ultrasonic spray pyrolysis.191 The main advantages of this
method compared to other conventional fabrication processes
are the rapid reaction rate and controllable reaction conditions,
as well as the ability to form NPs with uniform shapes, narrow
size distributions, and high purities.115 Wang et al.115 demon-
strated that ultrasound irradiation is favorable for the fabrica-
tion of uniform-shaped Bi2S3 nanorods, with a diameter
ranging from 20 to 30 nm, and a length of ca. 200–250 nm.
For that, Bi(NO3)35H2O and sodium thiosulfate (Na2S2O3) were
dissolved with distilled water, in the presence of triethanol-
amine as a complexing agent. This mixture was then subjected
to high-intensity ultrasound irradiation, using a high-intensity
ultrasonic probe (0.6 cm diameter; 20 kHz, 60 W cm2)
immersed in the solution, for 2 h, at room temperature.
However, when all the reaction conditions were kept the same
but thioacetamide was used as a sulfur source, shorter and
thinner Bi2S3 nanorods were obtained, which might be due to
the higher nucleation rate of Bi2S3 compared to the one
observed when Na2S2O3 is the sulfur source. Furthermore,
changing the complexing agents also affects both the nuclea-
tion and growth rates of Bi2S3, leading to the formation of
nanorods with different lengths and diameters. For example,
when EDTA was employed as a complexing agent, the Bi2S3
nanorods presented an average diameter of 15 nm and length
of 100 nm; while using sodium tartrate resulted in shorter
and more aggregated Bi2S3 nanorods with mean dimensions of
20  60 nm. Additionally, adding 20% N,N-dimethylformamide
(DMF) to the water solution increased the yield of the reaction,
and also decreased the dimensions of the Bi2S3 nanorods to
6  30 nm, due to the faster nucleation.
The presence of other surfactants in the precursor solution
can also affect the size of the Bi nanostructures prepared via the
sonochemical approach. In a study conducted by Zhang et al.,
Bi2O3 nanocrystals of different sizes were prepared after adding
PVP to the initial solution composed of Bi(NO3)35H2O in nitric
acid.194 This solution was slowly dropped into a NaOH aqueous
solution (pH = 11) under constant stirring, and the mixture was
then irradiated with high-intensity ultrasound (600 W, 20 kHz)
for 75 min. The particles prepared without PVP presented
diameters of 450–700 nm and lengths of 1–2.5 mm, and were
rod-like in shape; while in the presence of PVP, the Bi2O3 mor-
phology changed to granular grains, with a particle size ranging
from 40 to 100 nm. The Bi3+ ions might coordinate with PVP,
which decreases the Bi3+ concentration, and then the reaction
between the Bi3+ ions and OH is partially inhibited, leading to the
formation of smaller sized crystals.
Bi nanostructures can also be fabricated using a laser-
assisted approach, in which a laser beam is used to vaporize
or ablate Bi, and later the products are collected on a substrate
or then dispersed in a liquid.111 Different power sources have
been explored to synthesize Bi-based nanocomposites via a
laser-mediated approach. In the case of the pulsed laser radia-
tion in liquid technique, the size distribution of the pure BiNPs
can be tuned by changing the different parameters of the
laser, including the pulse energy, pulse duration, wavelength,
focalization spot, and repetition rate.124 Additionally, the laser-
mediated synthesis of pure BiNPs in aqueous solutions at
different pH values, such as water (pH 7), water + sodium
hydroxide (pH 9.7), or water + hydrochloric acid (pH 2.7) can lead
to the formation of different morphologies, such as spherical,
core–shell NPs, and hollow spheres, respectively.195
2.7. Bismuth-based nanocomposites
In addition to all of the techniques mentioned above, a diverse
range of Bi-based nanocomposites have been prepared in order
to improve the performance of BiNPs in different biomedical
applications, such as antibacterial materials, drug delivery,
cancer therapy, imaging, electrochemical sensors, and tissue
engineering.123,196 The combination of BiNPs with several types
of materials has been proposed, including with carbon-based
materials, bioactive glasses, inorganic NPs, and polymers (e.g.,
PVP and PEG).48,52,123,196–199 For example, the construction of
Bi heterojunctions with TiO2 or other materials,
200–203 doping of
various materials on BiNPs,204–207 as well as coating with various
polymers, have been greatly focused on in the fabrication of
Bi-based nanocomposites. Among all of these, the in vivo applica-
tion of polymer camouflaged Bi-based nanocomposites has been
highly studied as they show better stability in aqueous solutions
and prolonged circulation time in the bloodstream.198,208–210
Surface PEGylation,211 BiNP encapsulation into a polymeric
NP,212 layer-by-layer polymeric coating,213 and surface cross-
linking of polymers have been proposed214 as the main strate-
gies to hide BiNPs within a polymeric network. For example,
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hyaluronic acid (HA) modified Bi2O3 NPs were prepared using
a slightly modified procedure of the ‘‘polyol’’ method.214
As shown in Fig. 9, a transparent viscous solution of BiCl3
was first prepared in diethylene glycol (DEG). The solution was
then heated in a silicon oil bath at 140–160 1C for 1 h before
adding 7.5 mmol of NaOH dissolved in 30 mL of DEG. Next,
dissolved reactants were heated at 180 1C for 30 min under
vigorous stirring to obtain BiNPs, which were then further
modified with HA through stirring in a basic solution of HA
at room temperature for 6 h. In the next sections, Bi-based
nanocomposites are discussed more in detail, while describing
their fabrication approach along with highlighting their bio-
medical applications.
3. Biosafety and biodistribution of
BiNPs
With all the advances in NP-based formulations, the potential
toxicity has remained a challenging hurdle for their bench-to-
bedside movement. This is mainly due to the high chemical
reactivity and biological activity of the NPs as a result of their
ultra-small size, as well as their intimate contact with cell
membrane, internal organelles of cells, proteins and DNA.215,216
As one of the least toxic heavy metals, Bi has been clinically used
for many years to treat different diseases, such as peptic ulcers,
diarrhea, syphilis, severe acute respiratory syndrome (SARS), and
gastrointestinal disorders.217–220 The most common conventional
pharmaceutical formulations of Bi, including bismuth subcitrate
(De-Nol), bismuth subcitrate potassium (Pylera), bismuth subsa-
licylate (Helidac), and ranitidine bismuth citrate (Pylorid, Tritec)
have demonstrated very high safety. Nevertheless, there are
serious concerns with the in vivo toxicity of BiNPs, since compre-
hensive compatibility information on them ismissing and current
studies do not present the mechanisms behind the possible
cytotoxicity of these NPs at high concentrations.221 Therefore,
systematic studies on the generation of reactive oxygen species
(ROS), mitochondrial toxicity, cell membrane damage, and DNA
fragmentation, as the main mechanisms of NP-induced cellular
damage, are needed after cell exposure to various types of BiNPs.
It is speculated that, similar to many other types of nano-
materials, BiNPs usually possess dose-dependent adverse bio-
logical effects and their cytotoxicity is largely dependent
on particle diameter, charge, and surface modifications. For
example, the coating of Bi2S3 NPs by PVP, with the aim of
improving their biological stability, blood circulation time, and
safety, was found to keep HeLa adenocarcinoma cells alive at
high concentrations in a dose-dependent manner (Fig. 10a).222
PVP coating has also been shown to increase the dispersity of
NPs in aqueous medium without any detectable agglomeration,
resulting in slower elimination from the bodies of rats. The
leaching of free Bi3+ ions, which is one of the main mechanisms
of toxicity for BiNPs, is prohibited in the bloodstream.223 In
addition, long-term histological screening of the major organs,
including the heart, liver, spleen, and kidneys, showed no
tissue damage associated with the single-dose administration
of PVP–Bi2S3. PEG coating BiNPs can also reduce damage to
cells.208,224 PEG is a superior choice to modify the surface of
NPs with respect to the following benefits, including the
‘‘stealth’’ effect of PEG on improved blood compatibility, as
well as reduced protein corona formation and opsonization,
resulting in prolonged blood circulation.225 Nevertheless, in
contrast to the general assumption that PEG-conjugated NPs
lack antigenicity and immunogenicity, anti-PEG immuno-
globulin M (IgM) may be elicited after the introduction of
PEGylated NPs within the body.226,227 For active suppression
of immune attack and the prolonging of blood circulation, the
biomimetic coating of NPs by with the membrane of red blood
cells (RBCs) has been gaining increased attention.228 RBC
membrane has biologically friendly glycans, proteins and acidic
sialyl moieties, which endow them with high biocompatibility,
biodegradability, and non-immunogenicity. As shown in Fig. 10b1,
longer retention time in blood circulation was detected for the
RBC membrane-coated BiNPs (RBC-BiNPs) in comparison to
their bare counterparts, mainly due to the reduced NP uptake by
macrophages.229 In this study, folate modified RBC (F-RBC)-
coated BiNPs showed a similar blood circulation trend as the
ones camouflaged just using RBCmembrane, demonstrating the
negligible effect of folate on the circulation time. Compared to
the bare NPs, prolonged circulation of RBC-BiNPs resulted in
improved tumor accumulation via passive targeting 24 h post-
injection. Folate conjugation can further enhance the cellular
uptake of NPs by cancer tissue through combined passive and
active targeting as a result of the presence of the RBC cell
membrane and folate ligand, respectively (Fig. 10b2). Consider-
ing the high accumulation of the NPs in the liver and spleen,
these two are considered as dominant organs in the metabolism
of NPs, apart from their surface properties and coating
functionality.230,231 High safety, reduced clearance bymacrophages,
and enhanced accumulation in the tumor have also been observed
for mesoporous silica-coated Bi2S3 nanorods (BMSNR) encap-
sulated within platelet membrane (PM; Fig. 10c1). Inspired by
the in vivo stability of autologous molecules, elimination of the
exogenous Bi2S3 nanorods by macrophages was hindered after
loading within the PM. Meanwhile, binding affinity of the PM
to tumor cells resulted in active targeting of the 4T1 mammary
gland breast cancer cells in vivo, as shown in Fig. 10c2 and
c3.232 In contrast to the RBC cell membrane coating, the active
targeting observed for the latter example can be attributed to
the high affinity of the P-selectin on the surface of the PM for
cancer cells.233–235 Increased blood circulation time through
polymeric or cell membrane coating may lead to concerns
regarding the hemotoxicity of the BiNPs. Various reports have
recently revealed the desirable hemocompatibility of BiNPs,
showing a RBC lysing effect of lower than 5%,48,213,236,237 which
Fig. 9 A schematic diagram showing the procedure for fabricating
HA–Bi2O3 NPs.
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according to the criterion of the American Society for Testing
and Materials (ASTM) standards,238 is the highest acceptable
percentage of damaging potential of a foreign agent introduced
into the body.
Various in vivo models have also been developed to test the
toxicity of BiNPs. For example, Zheng et al.239 used a facile
solvothermal method to prepare Bi2S3 NRs by adding Bi neo-
decanoate (the precursor) to a mixture of oleic acid (OA) and
ethanol under stirring (Fig. 11a1). NRs were then obtained by
adding an oleylamine solution containing thioacetamide to the
above mixture under vigorous stirring. The sealed samples were
then heated at 150 1C for 10 h in an autoclave and finally cooled at
room temperature to separate Bi2S3 NRs by centrifugation. The
OA modified BRs were then further functionalized using amphi-
philic D-a-tocopherol PEG 1000 succinate (TPGS) to enhance their
aqueous compatibility. Finally, tetraethylorthosilicate (TEOS)
Fig. 10 (a1) A schematic representation of the synthesis and surface modification of oleic acid (OA) coated Bi2S3 nanodots with PVP. (a2) Cytotoxicity of
PVP-coated Bi2S3 nanodots on HeLa cells. (a3) Histological changes in the spleen and kidney of a rat one month after the intravenous injection of a single
dose of PVP-coated Bi2S3 nanodots. No significant changes in the normal morphologies of the tissues were observed, indicating the high safety of
the NPs. Adapted and reprinted with permission from ref. 222, Copyright 2011. (b1) The blood circulation of BiNPs (black curve), RBC-BiNPs (red curve)
and F-RBC BiNPs (blue curve) over a span of 24 h. (b2) The biodistribution of BiNPs (black), RBC-BiNPs (dense) and F-RBC BiNPs (sparse) in mice 24 h
post-injection. Adapted and reprinted with permission from ref. 229, Copyright 2018. (c1) A schematic representation of BMSNR@PM synthesis. Bismuth
sulfide nanorods (BNRs) were prepared via a solvothermal method. BNRs were decorated with mesoporous silica due to its well-defined structure and
desirable biosafety. PM was separated from whole blood and applied to camouflage the Bi2S3-mesoporous silica nanorods (BMSNRs) via sonication and
to obtain BMSNR@PM. (c2) The endocytosis of BMSNR@PM by macrophages (RAW264.7) and cancer cells (4T1) after 4 h of exposure to nanomaterials.
The increase in the cellular uptake by cancer cells after coating with PM is obvious. Blue and green signals indicate DAPI-stained nuclei and FITC-labeled
nanomaterials, respectively. (c3) Flow cytometry of RAW264.7 macrophage cells and 4T1 mammary gland breast cancer cells after treatment with the
nanomaterials for 4 h. Increased cellular interactions after coating with PM are observed for cancer cells. Adapted and reprinted with permission from
ref. 232, Copyright 2019.
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was added dropwise to a solution of the TPGS-modified Bi2S3
NRs and the final product was obtained after 10 min of stirring,
confirmed by elemental imaging of the particles (Fig. 11a2).
After synthesis, the Caenorhabditis elegans (C. elegans) worm
was used as a simple model organism to explore the safety and
biological response of orally administered Bi2S3@SiO2 NRs. The
accumulation of lipofuscin, an endogenous autofluorescent
biomarker of aging and oxidative degeneration of cellular
components, was investigated in C. elegans. Fig. 11a3 shows
that after 3 days of the exposure of C. elegans to NRs with
different concentrations, the autofluorescence intensity of the
intestine was not notably changed between the control group
and the groups treated with NRs, showing the negligible
adverse effects of Bi2S3@SiO2 NRs on the autofluorescence of
lipofuscin and its levels within the worm body. Bright field
imaging of the Bi2S3@SiO2 administered C. elegans was also
performed to ensure the uptake of NPs into the gut of the worm
(Fig. 11a4). In addition, no proliferation inhibition of the
C. elegans and negligible changes in the body length after 18 days
of exposure to various concentrations of the Bi2S3@SiO2 NRs up to
1000 mg mL1 were observed (Fig. 11a5). As a result of the CT and
photoacoustic tomography (PAT) imaging potential of the Bi2S3@
SiO2 NRs, this study suggested that BiNPs provide an alternative
way of fabricating multi-modal contrast agents that integrate
different imaging modalities for direct and non-invasive visualiza-
tion of the GI tract with minimal toxicity.
Fig. 11 (a1) A schematic illustration of the preparation process of Bi2S3@SiO2 NRs for bimodal CT/PAT imaging of the GI tract. (a2) A TEM image of
Bi2S3@SiO2 NRs and the elemental mapping of Bi, S and Si in Bi2S3@SiO2 NRs. (a3) The effects of Bi2S3@SiO2 NR treatments at concentrations of 0, 10, and
1000 mg mL1 (from left to right) on the accumulation of fluorescent lipofuscin in age-synchronized worms. (a4) A bright field image of the Bi2S3@SiO2
NR distribution in the GI tract of C. elegans. (a5) The body lengths of C. elegans after treatment with Bi2S3@SiO2 NRs with different concentrations.
Adapted and reprinted with permission from ref. 239, Copyright 2015. (b1 and b2) SEM and TEM images of BACP-2. (b3–b6) Morphological characteristics
of embryos at 28 hpf (b3) without injection and (b4) with the injection of 50 pg, (b5) 200 pg, and (b6) 400 pg of BACP-2. (b7) Body lengths of uninjected
embryos and embryos injected with BACP-2 at different concentrations at 28 hpf. (b8) The head areas of uninjected embryos and embryos injected with
BACP-2 at different concentrations at 28 hpf. (b9) Percentages of embryos with a small head and short body at 28 hpf in uninjected embryos and
embryos injected with different concentrations of BACP-2. (b10) Alcian blue staining of cartilage development at 5 dpf after the injection of BACP-2 at a
concentration of 400 pg. (a and c) A lateral view with the anterior to the left. (b and d) A ventral view of the pharyngeal cartilage. Scale bars = 500 mm.
Adapted and reprinted with permission from ref. 240, Copyright 2013.
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In another study, zebrafish embryos were used for the toxicity
assessment of Bi-asparagine coordination polymer spheres
(BACP-2).240 Zebrafish is a promising animal model for drug
formulation development because of the exclusive advantage of
their genome similarity to the human genome, easy imaging of
transparent embryos, well-characterized developmental stages, high
fecundity, and low-cost husbandry and housing.241–243 Spherical
BACP-2 with an average diameter of ca. 800 nm (Fig. 11b1 and b2)
was easily synthesized by preparing a transparent solution of Bi
nitrate (Bi(NO3)35H2O) and asparagine, followed by 24 h of
heating at 80 1C. Zebrafish embryos at cell stages 1–4 cell were
treated with 50, 200, and 400 pg of BACP-2 through micro-
injection and their development was evaluated by observing the
morphology of the embryos 28 h postfertilization (hpf) to
100 hpf. Fig. 11b3–b6 show smaller heads and shorter body
lengths at 28 hpf in the groups that received BACP-2 particles.
Quantitative analysis demonstrated concentration-dependent
toxicity as the percentages of embryos with shorter body
lengths and smaller heads constantly increased from 20% in
the control group to 38%, 65%, and 77% in the groups that
were injected with 50, 200, and 400 pg of BACP-2, respectively
(Fig. 11b7–b9). However, the evaluation of cartilage develop-
ment by alcian blue staining 5 days postfertilization (dpf)
demonstrated no harmful effect of the BACP-2 compared to
the uninjected embryos of the control group (Fig. 11b10). While
the toxicity of BACP-2 on zebrafish embryos was obvious, another
study showed that the number of viable chicken embryos
remained unchanged after treatment with Bi2O3/human serum
albumin (HSA) core–shell NPs, indicating normal functioning of
embryos after exposure to these NPs.244 These findings provide
new insights into the possible controversies and the necessity of
rigorous toxicity assessment for all types of BiNPs before their
application in biomedicine.
Murine models have also been used to investigate the in vivo
safety of BiNPs. For example, PVP coated Bi2Se3 nanoplates
were tested at a high dose of 20 mg kg1 in C57 male mice
through intraperitoneal injection, showing 93% metabolism
and clearance within 90 days.245 The liver, spleen, and kidneys
were the main target organs for Bi accumulation, reaching
concentrations of 163.2, 101.9, and 46.8 mg g1 in the afore-
mentioned organs after 1 day, respectively. Reticuloendothelial
systems (RES) play a main role in the dominant accumulation
of nanoplates within the liver and spleen compared to the other
organs.245 In general, no meaningful statistical differences were
observed over a 90 day period on the growth, body weight, and
thymus index of the animals, as well as the hematology
markers, biochemistry markers, and histology of various organs
between the nanoplate-treated mice and the control group.
Even small changes were negligible since the damages were
recovered to the normal state over the monitoring period of
90 days. For example, a meaningful change in the blood level
of alanine aminotransferase (ALT), as an indicator of hepatic
function, was observed on day 7 and recovered to the normal
level over the next screening time-points of 30 and 90 days.
Comparing the above system with other types of nanomaterials,
such as gold NPs (AuNPs) stabilized by PEG and bovine serum
albumin (BSA)246,247 or Fe3O4 nanocrystals coated with PEG or
OA,248 shows that coated BiNPs cause much less acute damage
and changes in the biochemistry parameters of the blood.
Another interesting study by Zhang et al.249 demonstrated not
only the high biocompatibility of PVP coated Bi2Se3 NPs at a
high dose of 50 mg kg1 in mice, but also their capability to
protect animals against ionizing radiation via their free radical
scavenging effect and electrocatalytic properties. In blood
circulation, Bi2Se3 NPs are prone to oxidation, and therefore,
they can provide a strong reducing effect for protection against
ROS and lots of free radicals generated by exposure to ionizing
radiation during the radiotherapy of cancer. It was found that
while the survival fraction of mice exposed to 662 keV gamma
photons was 0%, treatment with PVP–Bi2Se3 NPs protected the
animals from gamma radiation and increased the survival rate
to 70%. Additionally, NPs were gradually excreted for up to
90 days without any significant side effects in panels of clinical
biochemistry, blood chemistry, and pathology at a dose of
50 mg kg1. These NPs also improved the recovery of the
radiation mediated fall in the level of RBCs, white blood cells
(WBCs), and platelets. Promisingly, Bi2Se3 NPs also induced an
increase in superoxide dismutase (SOD; an enzyme that alter-
nately catalyzes the dismutation of superoxide radicals into
either ordinary molecular oxygen or hydrogen peroxide) and
reduction of 3,4-methylenedioxyamphetamine (MDA; a harmful
byproduct from mice) in animals exposed to ionizing radiation.
Therefore, it was conceived that Bi2Se3 NPs have great potential
to be used as adjuvant therapy to suppress radiation-induced
injuries. In fact, the Se released from the particles was hypothe-
sized to be able to reduce the side effects of RT through the
improved activity of glutathione peroxidase (GSH-Px) and SOD,
improving the radioresistance of healthy tissue.250 However,
to corroborate and extend the medical applications of BiNPs
towards this area, further in vivo explorations are needed.
The biosafety of nanomaterials, including BiNPs, is directly
related to their elimination from the body after administration.251
Clearance through the renal (urine) and hepatic (bile to feces)
pathways are two main routes for NP excretion.252 Renal clearance
needs glomerular filtration of nanomaterials in the kidneys, a
phenomenon that is highly dependent on the shape, charge, and
size of NPs. The typical filtration-size threshold (FST) of the
capillary walls of the glomerulus is nearly 6 nm. This means that
the filtration of nanomaterials with hydrodynamic diameters
larger than FST is not possible by the kidneys, unless they degrade
into smaller residues. If not, the Kupffer cells of RES capture large
NPs and digest them for clearance through the hepatic pathway
and later excrete them in feces. Most Bi-based NPs possess a
diameter larger than the FST threshold,38,50,121,253–256 therefore,
they cannot pass through the glomerular capillary walls and
be eliminated in urine. Even BiNPs with a size smaller than
6 nm can become larger in biological environments due to the
possible adsorption of plasma proteins on their surface. For
example, the size of Bi2S3 NPs has been shown to increase from
6.1 to 39.52 nm after BSA adsorption on their surface.257
Accordingly, similar to many other types of nanovehicles, hepatic
clearance seems to be the dominant route of elimination for
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BiNPs due to their large hydrodynamic diameter.53,258 In
general, BiNPs with any hydrodynamic size larger than the
FST, various shapes, different surface coating and chemical
composition have shown dominant accumulation in the liver
shortly after intravenous injection.229,232,245 However, the
synthesis of very small particles, surface coated with protein-
adsorption-resistant materials or using rapidly degradable
BiNPs might help to alter the clearance pathway towards the
urinary system.237,245,250,259 For example, Bi was easily detect-
able in kidneys 2 h after the injection of dextran coated Bi–iron
oxide nanohybrid.260 This shows that the Bi was efficiently
cleared through the urinary route as a result of particle degra-
dation in the acidic environment. The level of Bi in the urine
was found to be much higher than that of Fe due to the
confiscation of released Fe ions by ferritin for the synthesis of
hemoglobin, whereas such a system does not exist for the
consumption of Bi ions in the body. In addition, the incubation
of the nanohybrid in a 10% solution of fetal bovine serum
reduced their size from 98 to 48 nm after 24 h as a result of
time-dependent degradation in biological fluids, confirmed by
the detection of free Bi ions in the bio-mimicking media.
Similar to the above example, the accumulation of Cu3BiS3
NPs in the urinary system and their renal clearance were
dominant.259 This observation can be attributed to the small
size of the particles as well as the rapid chemical transforma-
tion and degradation of the Cu3BiS3 into Cu-COO
 species in
acidic lysosomal environment. Clearance through the kidneys
was also observed for (BiO)2CO3 nanotubes due to their rapid
disassembly in acidic environments, such as tumor tissue,
to nanoclusters with a size smaller than the FST, resulting
in their facile renal filtration within a short time post
administration.261 This study showed that the Bi content
excreted via the renal route reached ca. 35% within 12 h post
injection, while fecal clearance was lower than 2% during the
same time period. In contrast to the above examples that show
renal clearance of some BiNPs due to particle degradation,
Bi–Bi2S3 heterostructure NPs were removed from the body
through urine because of their own ultrasmall size.237 Therefore,
further assessments are necessary to understand the optimal
size and shape of BiNPs, which might guide their clearance
towards the renal system. Moreover, comprehensive studies on
the role of the route of administration and an understanding of
the relationship between the surface coating of BiNPs and their
clearance are still required.
4. Antimicrobial activity of BiNPs and
their composites
As the field of metal-based nanomedicine emerges, there is an
overwhelming number of studies on research surrounding the
topic of antimicrobial NPs due to the continuous occurrence
of bacterial resistance, which is a life-threatening challenge
worldwide.4,262–264 Nowadays, it is believed that some categories
of metallic NPs are good antimicrobial agents, because of their
high activity at low doses and diverse bactericidal effects,
providing the desirable potential to reduce or eliminate the
evolution of resistant bacterial strains.265 Mechanisms involved
in the antimicrobial effect of metal-based NPs include the
production of ROS, cation release from the NPs, ATP depletion,
membrane impairment and alteration of its respiratory
function, protein dysfunction and interference with nutrient
assimilation. These mechanisms even translate into alteration
of signal transduction and the inducing of destructive changes
to the microbial transcriptomic and proteomic profiles through
dephosphorylation of the peptide substrates on tyrosine
residues, resulting in the inhibition of signal transduction
and suppression of bacterial growth.262,266–269
The development and application of Bi in diverse forms
such as Bi salts, NPs, and nanocomposites as antimicrobials
have been increasingly investigated due to the biocompatibility
of Bi,270 creating new hope to fight infectious diseases and
bacterial resistance.163,271–279 For example, a combination of Bi
organic salts and some antibiotics are currently used to manage
Helicobacter pylori (H. pylori) infections.280,281 Likewise, Bi
carboxylates and Bi thiols show a capacity to treat H. pylori and to
inhibit biofilm formation.282,283 Hernandez-Delgadillo et al.273,274
reported the great antifungal and antibacterial properties of BiNPs
at low concentrations of 2 mM and less than 1 mM, respectively.
They showed the inhibitory effect of zerovalent BiNPs against
the growth of Streptococcus mutans (S. mutans) with a minimal
inhibitory concentration (MIC) of 0.5 mM and their ability to
inhibit biofilm formation similar to the antimicrobial effect
exhibited by chlorhexidine. The mechanism of action of these
zerovalent BiNPs was not described, but hypothesized to be
associated with the high surface-to-volume ratio of the parti-
cles, their quantum confinement, their stability in aqueous
media, and irregularities present in the crystal lattice of the
nanostructured BiNPs that provide more active sites to interact
with bacteria.273,274 Badireddy et al.,163,275 reported colloidal Bi
dimercaptopropanol (BisBAL) with an inhibitory effect on the
biofilm formation of Pseudomonas aeruginosa (P. aeruginosa)
and the inhibiting of the growth of S. mutans and S. gordonii by
over 70% at 0.1 mM (MIC = 5 mM). The mechanism of anti-
bacterial activity of the BisBAL NPs was postulated to be related
to the dissolution of the BiNPs and release of the Bi ions, which
could penetrate to the cell wall and then react with the
sulfhydryl groups of key respiratory chain enzymes to inactivate
and lyse bacteria.275 Similarly, Hernandez-Delgadillo et al.284
recently incorporated BisBAL NPs into a mineral trioxide aggre-
gate (MTA) to reduce the risk of infection, when MTA was used
in endodontic therapy. The Kirby and Bauer disk diffusion
method showed that the growth of Enterococcus faecalis
(E. faecalis), E. coli, and C. albicans could effectively be inhibited
by BisBAL NPs, demonstrating inhibition zones of 19, 24, and
23 mm, respectively. BisBAL NPs also showed antibiofilm
activity against E. faecalis at a concentration of 10 mg mL1
and exposure time of 24 h, suggesting that they are a good
candidate to decrease the incidence of dental re-infections after
the use of MTA in endodontic therapy. To highlight the role of
nanosized BiNPs, Cabral-Romero et al.274 showed the better
antimycotic effects of Bi2O3 NPs against C. albicans compared
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to other forms of Bi, including bulk polycrystalline Bi2O3 and
its precursor Bi nitrate, Bi(NO3)3, suggesting that the high
surface area of the nanostructured Bi2O3 was responsible for
its antimycotic activity, with a MIC of 1.5 mM. The hypothesis
for the antifungal mechanism of the Bi2O3 NPs relies on the
increased amount of water molecules and OH ions bound to
the surface of the particles, creating a highly negative surface
charge and basic aggregation points, to which C. albicans is
highly sensitive. Nevertheless, other mechanisms might be
involved in the antimicrobial potential of BiNPs. For example,
Nazari et al.276 prepared biogenic BiNPs through the inocula-
tion of Bi subnitrate with a pure culture of Serratia marcescens
and then demonstrated the multifaceted antimicrobial
potential of the particles against different strains of Gram-
negative H. pylori. An inhibitory dose of biogenic BiNPs
(100 mg mL1) caused the release of metabolites, such as
acetate, formic acid, glutamate, valine, glycine, and uracil from
H. pylori bacteria into their supernatant, suggesting that the
antimicrobial activity of BiNPs results from their interference of
the Krebs cycle, nucleotides, and acid metabolism. This multi-
faceted antimicrobial potential is the main reason for using Bi
subsalicylate NPs (BSS-NPs) in dental materials or antiseptic
solutions against oral anaerobic bacteria (e.g., Actinomyces
israelii, Aggregatibacter actinomycetemcomitans serotype b, Cap-
nocytophaga gingivalis, Eikenella corrodens, Fusobacterium nucle-
atum subsp. nucleatum, Parvimonas micra, Porphyromonas
gingivalis, Prevotella intermedia, Streptococcus mutans, and Strep-
tococcus sanguinis)278 or preparing Bi-substituted hydroxyapa-
tite nanopowders for potential applications in bone infection
and regeneration.285 Moreover, BiNPs and Bi nanocomposites
may also be used for combinatorial therapy of microbial infec-
tions by taking advantage of the radiosensitizing properties of
Bi,277 which can be combined with the antimicrobial effect of
antibiotics.286,287 Such synergistic effects may be an effective
way to kill multidrug-resistance bacteria through inducing
irreparable DNA damage due to the free radicals generated by
X-ray irradiation.198 Luo et al.277 have developed BiNPs surface-
modified with anti-P. aeruginosa antibodies to impart them
with selective X-ray mediated toxicity towards P. aeruginosa due
to the specific binding of the NPs to the bacteria, representing a
promising approach to accelerate the healing process in bac-
terial infected wounds. In addition to X-ray mediated antibac-
terial effects, Sharma et al.288 described visible the light-
induced bactericidal effects of octahedral monoclinic-Bi vana-
date (m-BiVO4) NPs towards E. coli. Similarly, the light-induced
ROS generation and photodynamic antibacterial effects of
BiNPs were also reported for nitrogen-rich carbon-coated Bi/
cobalt (Bi@Co@CN) NPs.289 Particles were fabricated via a
thermal condensation method using Bi(NO3)3 and Co(NO3)2
metal salts (Fig. 12a). Graphitic carbon nitride (g-C3N4) is an
antibacterial agent and the energy created by electron–hole
pairs enables it to generate ROS. However, rapid electron–hole
recombination limits its application as a potent antibacterial
agent. To overcome this limitation, g-C3N4 was decorated with
BiNPs, which has a narrow bandgap enabling it to harvest
visible light to generate thermal energy for a better
antimicrobial effect. Furthermore, Bi on the surface of g-C3N4
can facilitate charge transfer and accelerate electron–hole
separation, leading to enhanced photocatalytic activity. Co
was also used in this system because of its high photothermal
conversion effect to reduce the chance of infection recurrence
after using Bi@Co@CN as an antibacterial agent. In vitro find-
ings demonstrated the excellent antibacterial activity of
Bi@Co@CN against both Gram-positive (S. aureus) and Gram-
negative (E. coli ATCC25922 and Salmonella LT2) bacteria, as
well as methicillin-resistant Staphylococcus aureus (MRSA).
Within 20 min of treating a S. aureus suspension with the
Bi@Co@CN composite (2 mg of the composite in 10 mL of
bacterial suspension containing ca. 107 colony forming units
per mL) under visible-light irradiation, more than 99.9% of the
bacteria were killed due to the abundant generation of ROS and
thermal energy, imparting damage to the bacterial membranes
(Fig. 12b). Excellent charge separation efficiency between the
g-C3N4 nanostructures and metal NPs provided a desirable
antibacterial environment. In contrast, negligible antimicrobial
activity was observed in the dark and light controls. The
disinfection efficiencies of Bi@CN and Co@CN were also
significantly less than that of the Bi@Co@CN composite.
Fig. 12c displays the colonies of S. aureus on an agar plate after
exposure to Bi@Co@CN at various irradiation times, confirm-
ing the gradual killing of the bacteria with increasing illumina-
tion time. The role of ROS generation in the treatment of MRSA
infected wounds was also assessed in vivo, demonstrating very
effective wound healing without detectable damage to the
major organs (Fig. 12d and e). The suggested mechanism of
action is the inhibition of the expression and transcription
of virulence factors and the inhibition of the transcription of
methicillin resistant gene (mecA) of MRSA mediated by ROS
generation.
The same concept of inducing ROS generation was also
reported by Hsu et al.,290 by preparing biocompatible BiOI
nanosheets with high photocatalytic activity and energy storage
efficiency, and then, conducting in situ-doping of AuNPs and
gold–iodide (Au–I) complexes into BiOI nanosheets to render
the nanocomposites with high oxidase-like activity.291 Certain
volumes of Bi(NO3)2 (10 mM), KI (10 mM), and HAuCl4 (1, 10 or
100 mM) were added to a mixed solution containing ultra-pure
water and tris-borate buffer and this was allowed to react via
shaking in the dark for 2 h to form Au/BiOI nanocomposites.
Doping of AuNPs disrupted the layered crystalline structures of
BiOI, leading to the formation of a high degree of oxygen
vacancies and 4-fold higher oxidase-like activity compared to
the Bi nanosheets alone. In addition, the doping of AuNPs
reduced the MIC of the BiOI NPs from more than 400 mg mL1
to ca. 0.1–0.2 mg mL1. The very low MIC range of the Au/BiOI
nanocomposite, which indicates its highly efficient antibacter-
ial activity, was obtained for various bacteria, including E. coli,
K. pneumoniae, S. enteritidis, S. aureus, B. subtilis, and MRSA.
This was mainly due to the strong interactions of the nano-
composite with the bacterial membrane and higher generation
of ROS through the strong oxidase-like activity. The ROS gen-
eration induced bacterial killing via the destruction of cell
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membrane, inducing DNA and protein damage and disrupting
the electron transport of the bacterial membrane and respira-
tion processes. In this study, a S. aureus-infected bacterial
keratitis model was developed in rabbits to prove the effective-
ness of the nanocomposite on ocular infections. When com-
pared with Ag NPs, Au/BiOI nanocomposites showed better
maintenance of corneal thickness and lamellar structure of the
stromal layer, less inflammation, and higher biocompatibility.
In addition to ROS generation mediated by the photo-
dynamic antibacterials (PDA) discussed in the above examples,
photothermal antibacterials (PTA) of BiNPs have been recently
introduced to eradicate bacterial infections through the irradia-
tion of NIR (700–1100 nm) light.292 Light-to-heat conversion by
BiNPs can synergize the killing effect of ROS generation and
eradicate bacterial infections (Fig. 13a1). Novel Bi2Se3 nano-
plates (Fig. 13a2) were fabricated via a high-temperature
reaction (colloidal synthesis) and their surface was coated with
polyethyleneimine (PEI) through electrostatic interactions.293
These NPs, at a concentration of 80 parts per million (ppm),
were found to eradicate nearly 99% of S. aureus and around
97% of E. coli bacteria upon 10 min of NIR light irradiation
through combined PTT and photodynamic therapy (PDT) via
the generation of heat and ROS, respectively (Fig. 13a3 and a4).
Li et al.294 followed the same concept for the combined dual-
modal therapy of wounds infected by multidrug-resistant (MDR)
bacteria, using multi-functional heterojunctions of sheet-like
zinc atom-doped g-C3N4 and Bi2S3 nanorods (CN–Zn/BiS), which
were formed via the interspersion of clubbed BiS nanorods in
CN. Excellent photothermal properties of CN–Zn/BiS under
808 nm NIR irradiation were confirmed by observing stable
temperature variation and nearly constant maximum tempera-
ture during the on–off effects of the NIR laser. CN and CN–Zn
Fig. 12 (a) The fabrication process of Bi@Co@CN nanocomposites. Co(NO3)26H2O and Bi(NO3)35H2O were added into dimethylformamide (DMF) to
prepare a transparent solution, followed by the addition of 1,4-benzenedicarboxylic acid and triethylenediamine and 60 min of stirring. Finally, g-C3N4
was added to the solution mixture, which was stirred for 3 h before solvent separation and the heating of the remaining green solid powder at 800 1C for
1 h under an Ar atmosphere. (b) The density of S. aureus treated under different conditions by visible-light irradiation. (c) Bacterial colony growth in the
presence of Bi@Co@CN for different irradiation times. (d) A schematic illustration of the mechanism of action of Bi@Co@CN, with the generation of ROS
and thermal energy, enhancing the photodynamic inactivation of the bacteria under visible-light irradiation. (e) Photographs of infected wounds during
treatment with PBS, Bi@CN, Co@CN, and Bi@Co@CN, showing clear incrustation in the Bi@Co@CN group after 4 days of treatment. Adapted and
reprinted with permission from ref. 289, Copyright 2019.
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did not show any significant killing effect towards MRSA at a
concentration of 200 mg mL1 under 808 nm NIR irradiation.
In contrast, 70.3% and over 99.2% of MRSA were killed under the
same conditions after exposure to BiS and CN–Zn/BiS, respectively
(Fig. 13b1 and b2). The nanocomposite also regulated inflamma-
tory factors, such as IL-1b and IL-6 in vivo (Fig. 13b3) to accelerate
the regeneration of infected wounds after killing the bacteria via
NIR therapy. Fig. 13b4 summarizes the combined PDA/PTA anti-
microbial mechanisms of the CN–Zn/BiS nanocomposite. The
pernicious effects of ROS and hyperthermia decreased F-type
ATP and increased ortho-nitrophenyl-b-galactoside (ONPG) hydro-
lysis, resulting in damage to electron transport in the respiratory
chain, membrane polarization and protein leakage from the
bacterial wall. It is worth pointing out that combined anti-
bacterial and anti-inflammatory effects, similar to the above
example have also been reported by Ouyang et al.295 who showed
selective cell wall disruption and eradication of Gram-positive
S. aureus bacteria by Bi2Se3 nanodiscs (50 mg mL
1) due to the
high affinity of the nanodiscs towards lipoteichoic acid on the
surface of the bacteria. Furthermore, Bi2Se3 was found to be
capable of scavenging the intracellular ROS of macrophages and
reducing inflammation through a decrease in inflammatory
cytokines, endowing them with high efficacy to treat infected
wounds. Nevertheless, there is a controversy between these two
studies due to the lack of information on the work performed by
Li et al. While Ouyang and his team achieved anti-inflammatory
Fig. 13 (a1) A high-magnification SEM image of a Bi2Se3 NP. (a2) The antibacterial effects of PEI coated Bi2Se3 NPs as a function of concentration.
Bacterial viability is presented as a percentage under the different conditions of no laser, PDT alone and combined PDT and PTT for S. aureus (left graph)
and E. coli (right graph). Adapted and reprinted with permission from ref. 293, Copyright 2018. (b1) MRSA strain counts calculated from spread-plate
assays after exposure to CN, CN–Zn, BiS, or CN–Zn/BiS (200 mg mL1) under 808 nm NIR light irradiation. (b2) Live/dead fluorescence staining of MRSA.
Green fluorescence from live bacteria stained using SYTO9 dye and red fluorescence from dead bacteria stained using propidium iodide (PI) dye were
detected. (b3) The quantification of inflammatory IL-1b and IL-6 cytokines in wound tissues after 2 days of treatment with CN, CN–Zn, BiS, or CN–Zn/BiS.
(b4) The antibacterial mechanism of PDA/PTA induced by CN–Zn/BiS under 808 nm light irradiation. Adapted and reprinted with permission from
ref. 294, Copyright 2019.
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responses through reduced ROS production by Bi2Se3, Li et al.
used CN–Zn/BiS for NIR-mediated ROS production for bacterial
killing, while still demonstrating reduced secretion of inflam-
matory cytokines, such as interleukin (IL)-1b and IL-6. In this
study, we were not able to realize whether the anti-inflammatory
tests were performed after treatment with CN–Zn/BiS alone or in
combination with NIR irradiation and subsequent ROS produc-
tion, which presumably increases the secretion of inflammatory
cytokines instead of their suppression. Therefore, further studies
are needed to identify the main aspects of the effects of Bi on
immune reactions.
In addition to its nanoform, Bi may also be incorporated in
other structures such as nanocellulose matrices,296 nanoneedles,297
and implants298–300 for antimicrobial applications. As a result of the
known antimicrobial properties of Bi, and since organophosphorus
compounds, in particular phosphinic acids, are known for
their antibacterial properties,301 Werrett et al.296 investigated
the synergistic effects of Bi(III) and phosphinate ligands towards
MDR bacteria, by incorporating Bi-phosphinato complexes into
microfibrillated nanocellulose to prepare Bi-cellulose paper
sheets. The Bi-paper composites showed potent antibacterial
activity against different bacteria (S. aureus, MRSA, vancomycin-
resistant enterococci, E. coli). The Gram-positive bacteria were
found to be more susceptible than Gram-negative E. coli, prob-
ably due to the double membrane of the latter. Interestingly,
for all bacterial strains except E. coli, the bi-phosphinato
complex composites outperformed the silver standard and their
meaningful potential for usage in surface coatings, packaging
and/or medical devices were suggested. As another example,
Indurkar et al.297 fabricated Bi2O3 nanoneedles with an average
size of 158 nm and lengths of 1–3 mm via a green route using
D. alata tuber extract for the first time. The antifungal activity
of the nanoneedles (MIC = 0.0625 mg mL1) against C. albicans
was 4-fold higher than that of the Bi2O3 bulk powder (MIC =
0.250 mg mL1) and 2-fold higher than the model drug itraconazole
(MIC = 0.125 mg mL1). Several studies are also available on the
coating of titanium implants using Bi in its crystalline form or
Bi-derived compounds to render implantable devices with anti-
bacterial properties.298–300,302 For example, using a live and dead
fluorescence staining technique, Gosau et al.298 demonstrated
the better antimicrobial activity of Bi-coated implants against
S. epidermidis when compared to silver or copper-coated implants,
suggesting that Bi can be used as a new coating material for
preventing biofilm formation on dental implants.
The utilization of Bi for antibacterial effects reveals that it
has great importance in the future development of NP-based
and implant-based therapeutics, not only for antimicrobial
treatment, but also as a prevention measure to avoid infection
due to treatment. This field seems to be in its infancy, where
studies have mainly focused on the proof-of-concept demon-
strations of the in vitro antimicrobial activity of the developed
platforms. In this regard, it is urgent to progress to more in vivo
preclinical studies where the antimicrobial properties of
Bi-based materials may be practically tested. It is anticipated
that Bi-based antimicrobial composites may offer potential
antimicrobial activity against many pathogens with activities
similar or superior to products under clinical trial or already
commercially available metal-based nanocomposites, such as
silver (Acticoatt)303 and Au (Auranofin)304 nanocomposites.
5. Drug delivery and targeting by
bismuth-containing nanomedicines
The rapid growth of medicine has stimulated the development of
new approaches for drug delivery by which the introduction of
therapeutic substances is improved with respect to their efficiency
and safety through the control of the rate and place of drug release
in the body for various diseases, such as cancer and bacterial
infection.11,305,306 From a technological point of view, the synthesis
of new drugmolecules is expensive and time-consuming, therefore
scientists prefer to work on the formulation design of available
drug molecules to introduce new methods of making them more
accessible to the human body in an efficient manner. Nanoscale
particles generated by organic and inorganic molecules have been
widely investigated for this purpose in different ways.307 For
instance, BiNPs stabilized by polyvinylpyrrolidone (PVP) have been
found to assist in the NIR light-responsive release of metformin,
an anti-diabetic drug, from microneedles (MNs) coated with lauric
acid (LA) as a thermally-responsive material.308 BiNPs were the
part of the formulation that induced the conversion of NIR light
to heat, in order to melt the MNs and induce drug release.
Transdermally administered MNs, compared to subcutaneous
(SC) injection, remarkably induced the hypoglycemic effect
in vivo for the treatment of diabetes.
One of the main challenges of BiNPs in drug delivery is the
small space in their structure for the loading of therapeutic
agents. Researchers have focused on developing novel BiNPs to
improve their capacity for carrying drug molecules.81,261,309 In
this respect, Bi2S3 nanourchins (Bi2S3–PEG NUs) with a highly
porous structure were fabricated using Bi2O3 nanospheres (as
the Bi precursor), and then, these were PEGylated for enhanced
stability.236 To fabricate the particles, Bi(NO3)35H2O was com-
pletely dissolved in HNO3 solution, and then, NaOH, PVP and
EG were added into the mixture, which was then heated at
150 1C for 3 h. Bi2O3 nanospheres were obtained after cooling
the mixture down and centrifuging the sample. The Bi2O3
nanospheres were dispersed in a solution of thioacetamide
and heated at 150 1C for 12 h to obtain black Bi2S3 nanourchins.
The final PEG-coated Bi2S3 nanourchins were prepared by dis-
persing the samples in a PEG-SH solution under ultrasonication
and then stirring overnight (Fig. 14a1). TEM images (Fig. 14a2)
reveal their urchin-like morphology, with an average diameter of
the inside of the sphere ofB137 nm. In addition, the porosity of
the Bi2S3 nanourchins was explored via Brunauer–Emmett–
Teller (BET) analysis of their nitrogen adsorption–desorption
isotherms, demonstrating the higher porosity and surface area
of Bi2S3 nanourchins compared to Bi2O3 nanospheres, making
them capable of higher drug loading, in this case doxorubicin
(DOX), and enhanced cellular interactions, respectively. The
Bi2S3 nanourchins were found to be stable in water, but rapidly
aggregated in physiological solutions, such as PBS, owing to an
Review Article Chem Soc Rev
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 3
0 
Ja
nu
ar
y 
20
20
. D
ow
nl
oa
de
d 
on
 4
/2
4/
20
20
 9
:5
3:
22
 A
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
This journal is©The Royal Society of Chemistry 2020 Chem. Soc. Rev., 2020, 49, 1253--1321 | 1279
electron screening effect (Fig. 14a3). PEG-SH was able to steadily
attach onto the surface of Bi2S3 through metal–S ligands to
enhance the aqueous dispersity and stability of the particles in
various physiological solutions. In addition to these benefits,
PEGylation enhanced the blood circulation of the NPs and
promoted their homing into the tumor region of BALB/c nude
mice (subcutaneously developed by the injection of HeLa epithe-
lial adenocarcinoma cells) through enhanced permeability
and retention (EPR) effect when applied for cancer therapy.
PEG exhibits resistance to confiscation by the RES organs, and
therefore, the leaky vascular structure and impaired lymphatic
drainage of cancerous tissue presumably allow the localization
of cargos of PEG-coated BiNPs within the tissue. To confirm this
hypothesis, multifunctional Bi2Se3@PEG nanocapsules (BP NCs)
loaded with chlorin e6 (Ce6) and DOX were prepared following
the procedures shown in Fig. 14b1.40 Bi2O3 nanospheres were
first formed following the same protocol used in the previous
example.237 Bi2Se3 NCs were subsequently prepared based on a
hydrothermal process, by dispersing Bi2O3 nanospheres in a
solution of ascorbic acid and Na2SeO4 in water and heating it
up to 150 1C for 12 h. PEG-SH was again used here for the
PEGylation of the obtained hollow mesoporous Bi2Se3 NCs,
which were subsequently loaded with Ce6 and DOX to prepare
Bi2Se3@PEG/DOX/Ce6 (BPDC) NCs. The morphology of the
particles in each step is shown in Fig. 14b2. Prolonged blood
circulation and efficient EPR mediated accumulation of DOX in
a subcutaneously inoculated 4T1 mammary gland breast cancer
cell model was detectable when the drug loaded BPDC NCs were
administered (Fig. 14b3). Similar to this study, DOX and Ce6
co-loading within PEGylated star-like Bi2S3 NPs, which were
Fig. 14 (a1) A schematic representation of the synthesis of Bi2S3–PEG nanourchins. (a2) TEM images of the Bi2O3 nanospheres and Bi2S3 nanourchins.
(a3) Digital photos of Bi2S3 and Bi2S3–PEG nanourchins dispersed in water and PBS, showing improved stability in salt solution after the PEGylation.
Adapted and reprinted with permission from ref. 236, Copyright 2016. (b1) A schematic depiction of the procedure for fabricating mesoporous hollow
BPDC NCs as a multifunctional drug delivery platform. (b2) TEM images of Bi2O3 NPs, Bi2Se3 NCs and BPDC NCs are shown from left to right (scale bars
are 50 nm). (b3) The blood concentration of DOX loaded BPDC NCs or free DOX over 24 h after intravenous administration to mice (left) and the
biodistribution of DOX loaded BPDC NCs or free DOX 24 h post-injection into BALB/c mice bearing 4T1 tumors (**po 0.01 between the two groups).
Adapted and reprinted with permission from ref. 40, Copyright 2019.
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prepared via the thioacetamide treatment of Bi2O3 NPs, was also
reported.49 The hydrodynamic size of the drug encapsulated
particles was 272.8 nm and their negative surface charge was
expected to benefit their long blood circulation.310
In addition to the above strategies offered for drug encap-
sulation within the BiNPs, direct surface conjugation of the
drug molecule to the particles,311 loading of the therapeutics
into a mesoporous shell surrounded around the BiNP core,312
as well as combined loading of the drug and BiNPs into a
nanosized polymeric hydrogel12 have been investigated. For
example, Bogusz et al.311 fabricated a-Bi2O3 NPs that were
linked with methotrexate (MTX) through (3-aminopropyl) tri-
methoxysilane (APTMS) in a core–shell structure. The a-Bi2O3
NPs were first coated with APTMS and then conjugated to MTX
through amidation between the amine moieties on the shell
and the carboxylic acid groups of MTX molecules. MTX was
released from the surface of the NPs via cleavage of the amide
bond at low pH. As for the second approach, mesoporous silica-
coated Bi2S3 (Bi2S3@MSN; Fig. 15a1) NPs were reported for
the encapsulation and protection of DOX.313 Interestingly, NIR-
responsive drug release was observed from the nanocomposite,
as a laser power density of 1 W cm2 induced the release
Fig. 15 (a1) A TEM image of Bi2S3@MSN. Scale bar is 100 nm. (a2) The drug release profile during NIR laser irradiation for 10 min. The drug was not released
without applying a NIR laser (data not shown). (a3) Flow cytometry analysis of the in vitro active targeting effect of RGD–Bi2S3@MSN in UMR-106 cells
stained by free FITC, FITC–Bi2S3@MSN, and FITC–RGD–Bi2S3@MSN. (a4) The quantitative measurement of the mean fluorescence intensity of different
groups from (a3). Adapted and reprinted with permission from ref. 312, Copyright 2018. (b) The synthesis process of DOX/Bi@CMC. Adapted and reprinted
with permission from ref. 12, Copyright 2019. (c) A schematic depiction of Bi2Se3-CS-RGD synthesis as a targeted theranostic nanomedicine, proposed for
in vivo imaging-guided cancer RT. Reprinted with permission from ref. 314, Copyright 2017. (d) A schematic illustration of the final design of folate
conjugated perfluorohexane core–lipid shell particles carrying Bi2S3 NPs in the lipid compartment. Reprinted with permission from ref. 39, Copyright 2016.
(e) A schematic illustration of preparing HA–DS hydrogel loaded with DOX and BiNPs. Reprinted with permission from ref. 315, Copyright 2018.
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of 30% of the drug from the NPs (Fig. 15a2). This feature is
highly desirable for tumor therapy, since NIR laser irradiation
is only applied at the site of the tumor during treatment and the
controllable local release of DOX would therefore efficiently
reduce the side effects experienced by normal surrounding
tissues. In addition, an arginine-glycine-aspartic acid (RGD)
peptide was covalently conjugated on the surface of the nano-
composite to endow the carrier with active targeting and
uptake by UMR-106 epithelial cancer cells (Fig. 15a3). Similar
to this study, successful active targeting of the tumor cells
was reported using LyP-1 peptide conjugated PEG–Bi2S3 NPs,
210
Trastuzumab (Tam) conjugated Bi2S3@MSN core–shell NPs,
313
chitosan (CS)-RGD modified Bi2Se3 nanosheets (Fig. 15c),
314
and folate conjugated perfluorohexane core–lipid shell parti-
cles carrying Bi2S3 NPs in the lipid shell (Fig. 15d).
39 As an
example of the last approach, which is the combined loading of
the drug and BiNPs into a nanosized polymeric hydrogel, Xuan
et al.12 used a combined solution of carboxymethyl cellulose
(CMC) and Bi citrate (BC) as initial safe materials to prepare a
BiNP imbedded nanohydrogel (Bi@CMC; Fig. 15b). CMC was
first dissolved in water and then combined with an aqueous
solution of BC-containing ammonia. The mixture was then
diluted with water and the pH was adjusted to 7.0 using 1 M
HCl. Next, 300 W UV lamp irradiation was applied for 4 min to
obtain and collect Bi@CMC via centrifugation. The loading of
DOX was achieved by stirring 40 mg of DOX and 1 mg of
Bi@CMC in 5 mL of PBS for 12 h in the dark. In addition to
the loading of the BiNPs into the matrix of the nanohydrogels,
their incorporation within injectable bulk polymeric hydrogels
has also been investigated for cancer therapy.315 This work was
performed to achieve the sequential delivery of BiNPs and DOX
for a synergistic anticancer effect via combined X-ray radio- and
chemo-therapy (Fig. 15e). A hyaluronic acid–dextran sulfate
(HA–DS) macroporous hydrogel was prepared through the
redox-initiated polymerization of methacrylated hyaluronic
acid (MAHA) and methacrylated dextran sulfate (MADS) in
PBS under frozen conditions. First, 1 mL of tetramethylethyl-
enediamine (TEMED), 0.5 mL of ammonium persulfate (APS),
and 6.5 mL of PBS were added to a solution containing 4 mL of
MADS (50 mg mL1 in PBS) and 8 mL of MAHA (50 mg mL1
in PBS). The mixture was then incubated for 17 h at 20 1C
before heating to room temperature to remove ice crystals and
subsequent washing with PBS for 0.5 h. DOX loading was
performed by adding a PBS solution of the drug solution into
a mixture of MAHA, MADS, TEMED, and APS before the cooling
step. BiNPs were encapsulated by rehydration of the dried
hydrogel with the solution of BiNPs. The loading efficiencies
of the drug and BiNPs into the HA–DS hydrogel were found to
be 83.8% and 85.7%, respectively. The hydrogel offered sequen-
tial delivery profiles for co-loaded BiNPs and DOX. BiNPs were
released completely over 24 h, while the release profile of DOX
was very slow over the first 24 h and continued over one week,
resulting in a survival rate of 100% in mice through a synergis-
tic anticancer effect on a 4T1 mammary gland breast cancer
tumor-bearing mouse model mediated by combined X-ray
radio- and chemotherapy.
Taken together, these findings on the drug delivery and
targeting potential of BiNPs provide insights for broadening the
investigation of these carriers in precision medicine. This is
mainly due to the possibility of combining these assets with
multi-modal bioimaging and BiNP-mediated PTT, which are
comprehensively highlighted in the coming sections.
6. Contrast-enhanced diagnostic
imaging using BiNPs
The contrast of the image is the main criterion for defining the
sensitivity of a diagnostic imaging method. In general, higher
contrast efficacy is urgently needed to reduce the side effects
caused by the high dose administration of contrast agents in
clinical imaging.316–319 BiNPs have demonstrated high potential as a
powerful contrast agent for different imaging modalities.38,54,236,320
As a result of the presence of Bi, these versatile NPs have recently
been employed for dual-modal and multi-modal imaging guided
therapies for precise diagnosis andmonitoring of treatment process.
Scientists are currently shifting from single imaging modality,
which usually cannot meet favorable diagnostic requirements,
to the combination of different accurate imaging modalities
using a single formulation of BiNPs, implying that they can act
as novel contrast agents (CAs) and move from the bench to the
bedside in the near future.212
In this section, a comprehensive overview of the recent
advances in the area of BiNP-based imaging is provided to
demonstrate the feasibility of creating contrast-enhanced
multi-diagnostics using these NPs.
6.1. Computed tomography (CT) imaging using BiNPs
CT imaging is considered to be one of the most popular
imaging modalities owing to the possibility of deep-tissue
imaging with high resolution.321 Bi possesses a higher K-edge
value (90.5 keV) and larger X-ray attenuation coefficient
(5.74 cm2 kg1 at 100 keV) than other X-ray contrast agents,
such as iodine (I), barium (Ba), gadolinium (Gd), ytterbium
(Yb), tantalum (Ta), tungsten (W), and Au, making it an
excellent CA for CT imaging.322,323 Furthermore, the low price
and high biosafety of Bi,198 compared to other elements used
for the formation of NP-based X-ray contrast agents, have added
more value to its application as a CA. For example, Bi is nearly
2000 times cheaper per mole and has double the terrestrial
abundance of Au,120 which are attractive criteria from an
economical point of view. Moreover, Bi-containing medicines
have been applied clinically for more than three centuries at
relatively high doses,324 thus their biosafety has been more
explored compared to other heavy metal-based nanoagents
such as AuNPs. Evaluation of the CT contrast performance of
Tween 20 coated Bi2S3 nanorods (NRs; Fig. 16a1) revealed that
the Hounsfield units (HU) slope of the particles is 39.36, which
is much higher than that of iopromide, which has a HU of
16.38.38 TEM images of the Bi2S3 NRs show a uniform size
with a diameter of around 10 nm and a length of up to 50 nm
(Fig. 16a2). The size was increased to about 90 nm after
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modification and formation of a condensed Tween layer on the
surface, as illustrated in the inset of Fig. 16a2. CT imaging of
tumor-bearing mice revealed a collection of remarkable CT
contrast signals in the tumor 3 h post injection, confirming
the sufficient accumulation of NRs at the site of interest
(Fig. 16a3). In addition, the vasculature was hyperattenuating
5 min post intravenous (IV) injection of Bi2S3 NRs and led to
clear angiography with contrast filling of the heart, vena
cava, vena epigastrica, pulmonary vein plexus, tumor surface
vascularity, and tumor microvessels (Fig. 16a4), demonstrating
the great potential for the use of Bi2S3 NRs in the diagnosis of
vascular disease and tumor imaging. The surface coating of the
NRs with Tween 20 favored an efficient EPR effect and long
residence time of the particles in the tumor for CT imaging.
PEG-coated Bi2S3 nanodots have also demonstrated favorable
accumulation in the tumor tissue.325 Nevertheless, compared to
the previous example, ultra-small size of these nanodots would
render them with the benefits of efficient penetration into a
deeper area of the tumor followed by efficient clearance from
the body after imaging.
Double or multiple-component BiNPs,326 similar to the
above examples, confine the amount of Bi in the particles,
and as a consequence, higher concentrations of the NPs are
needed in order to achieve sufficient CT contrast. It is demon-
strated that the Bi content in the Bi2S3 NPs is nearly half that of
pure BiNPs of identical size.327 Therefore, the synthesis of pure
metallic BiNPs has been of recent interest as the most effective
way of promoting CT imaging potential.213 Li et al.213 developed
PEGylated metallic Bi nanocrystals (Bi–PEG NCs) for the first
time as a competent diagnostic agent for high-performance CT
imaging. The Bi NCs were first synthesized via a chemical reduction
method from readily available Bi(III) nitrate in D-(+)-glucose
saturated 1,2-propanediol (PPD). Borane morpholine, dissolved
in PPD, was added into the above solution to activate the
reaction at 80 1C under stirring, in which the mixture turned
black very rapidly as an indication of the formation of the
Fig. 16 (a1) A schematic illustration of the design of Tween-Bi2S3 NRs for EPR-based CT imaging. (a2) TEM images of Bi2S3 NRs, as well as the size
distribution of Tween-Bi2S3 NRs measured via dynamic light scattering (DLS). (a3) In vivo X-ray CT imaging in 4T1 tumor-bearing mice. The left image
shows the cancer tissue in the white circle before injection. The middle image demonstrates the tumor area in the white circle 5 min post IV injection of
the Tween-Bi2S3 NRs. The right image shows the cancer tissue of the mice 3 h post-intravenous injection of the Tween-Bi2S3 NRs. Liver (L), spleen (S),
and tumor (T) are shown in the images. (a4) CT images of the mice 5 min post IV injection of the Tween-Bi2S3 NRs to highlight the vascular structures. The
numbers 1 to 6 correspond to the heart, vena cava, pulmonary vein plexus, vena epigastrica, tumor surface vascularity (from the abdominal venous
branch), and tumor microvessels (TMV), respectively. Adapted and reprinted with permission from ref. 38 Copyright 2015. (b1) A schematic depiction of
the synthesis of the Bi–PEG NCs. (b2) 3D in vivo CT images of the tumor-bearing mice before (Pre) and 6 h after the IV injection of the Bi–PEG NCs
(5.0 mg mL1, 200 mL). Adapted and reprinted with permission from ref. 213, Copyright 2017.
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Bi NCs (Fig. 16b1). Since the bare Bi NCs were susceptible to
aggregation and rapid oxidation when dispersed in water for
one week at room temperature, they were functionalized with
PEG after layer-by-layer polymeric coating, as shown in Fig. 16b1.
Negatively charged Bi NCs were sequentially coated with cationic
poly(allylamine hydrochloride) (PAH) and anionic poly(acrylic
acid) (PAA) via electrostatic adsorption, while 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) was used in the last
step to covalently conjugate PEG-NH2 on the surface of the
particles through the formation of amide groups with the
carboxyl groups of PAA. The zeta potential of the bare Bi NCs
increased from 10 to +36 mV after the fabrication of Bi@PAH,
and subsequently decreased to 19 mV after PAA coating.
Successful layer-by-layer assembly was further confirmed via
the observation of a constant but slight enhancement of the
average hydrodynamic size after each coating step. The CT
contrast signals were first measured by acquiring phantom
images of the aqueous suspensions in vitro, and comparing
them with those of high performance CT contrast agent, i.e.,
Bi2Se3 nanoplates.
328 Images with a higher resolution and
brightness were obtained with Bi–PEG NCs since the signal
from these particles was much higher than that of the Bi2Se3
nanoplates. The X-ray absorption coefficient of the Bi–PEGNCs was
as high as B60.3 HU mL mg1, 2.3-fold greater than that of the
Bi2Se3 nanoplates (B26.2 HU mL mg
1) and 3.7-fold greater than
clinically-available iopromide (B16.4 HU mL mg1). To the best of
our knowledge, this is one of the highest values so far reported for a
CT contrast agent, when compared to Bi2S3 nanorods,
38 PEGylated
Bi2S3 nano-urchins,
236 PEGylated Fe@Bi2S3 NPs,
54 or Au-, Pt-, W-, or
Ta-based CT contrast agents.329–333 In vivo CT imaging of HeLa
adenocarcinoma tumor-bearing Balb/c mice demonstrated weak
CT signals in the cancerous tissue before the intravenous injection
of Bi–PEG NCs (5.0 mg mL1, 200 mL), while EPR phenomenon
and efficient passive accumulation of the particles in the tumor
resulted in a gradual increase in the signal to its maximum
level 6 h after injection (Fig. 16b2). The signal then decreased
slowly and lasted up to 24 h.
The concept of single component BiNPs for X-ray imaging
was further studied by Yang et al.72 through the fabrication of
1,2-dilauroyl-sn-glycero-3-phosphocholine (DLPC) BiNPs (denoted
as Bi@DLPC NPs), with a desirable size of 47  3 nm (Fig. 17a).
Herein, Bi(III) acetate, dissolved in a mixed solution of OA and
1-dodecanethiol, was used as a precursor for the formation of
BiNPs. The mixture was first heated at 40 1C for 30 min under
vacuum, followed by a temperature increase up to 100 1C in the
presence of nitrogen. The monodispersed BiNPs were then rapidly
obtained by treating the transparent yellow solution of the previous
step at 100 1C with trioctylphosphine solution containing
1-dodecanethiol. Bi@DLPC NPs were prepared by ultrasonic treat-
ment of the mixed BiNPs and DLPC vesicles in deionized water for
10 min. The CT imaging properties of the Bi@DLPC NPs were
found to be concentration dependent and the signal intensity, as
well as HU values, remarkably increased when the concentration of
the NPs increased from 0.313 to 5 mg mL1 (Fig. 17b and c).
In both abovementioned examples of single-component
BiNPs, the size of the NPs was bigger than 40 nm, which is
not optimal for desirable EPR-based accumulation in the tumor
and subsequent non-toxic clearance from the body through the
urinary system. Taking this into account, other studies have
presented ultra-small Bi–PEG nanodots with a size of ca. 4 nm334
and PVP-protected Bi nanodots with a size of ca. 2.7 nm,335 which
might presumably work better for tumor imaging at very low
concentrations due to their higher accumulation in the cancer
tissue. In addition, since the size of these particles is less than
the FST of the capillary walls of glomerulus, they are theoreti-
cally able to be easily cleared from the urinary system instead of
their long-term accumulation in the liver and spleen.
6.2. Photoacoustic (PA) imaging and infrared thermography
(IRT) using BiNPs
Photoacoustic imaging (PAI) is an emerging noninvasive
diagnostic technology that employs the photoacoustic (PA)
effect to overcome the high degree of scattering of optical
Fig. 17 (a) A TEM image of Bi@DLPC NPs (left) and the corresponding EDS
elemental mapping analysis. Bi (red) and phosphorus (green) were identi-
fied in the elemental analysis, confirming the successful DLPC coating
outside of the BiNPs. (b) In vitro CT images and (c) the corresponding HU
values of various concentrations (mg mL1) of Bi@DLPC NPs. Adapted and
reprinted with permission from ref. 72, Copyright 2018.
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photons in biological tissue, thereby resulting in higher spatial
resolution of images obtained from living subjects.336 Com-
pared to other optical imaging approaches, this technique is
advantageous for visualizing deeper tissues when CAs with
efficient photothermal conversion are used.337 Light absorption
by PA CAs induces a thermally induced pressure jump that
produces ultrasonic waves, which are then received by acoustic
detectors to form PA images.338,339 BiNPs are expected to play
this role via their desirable photothermal conversion efficiency in
the NIR window. Bi2S3 nanorods
340 with a size of 155.4  2.8 nm
and Bi2Se3 nanosheets
28 with sizes of 3 and 80 nm are examples of
PAI using BiNPs. In the latter study, Xie et al.28 showed that BiNPs
of smaller size were more promising for PAI. This could be
associated with the lower scattering introduced by the smaller
Bi2Se3 nanosheets, by which the external NIR light could be
proficiently absorbed instead of being scattered.341 This led to
effective photothermal conversion and higher thermal expansion
that synergistically promoted the PA conversion capability of the
smaller nanosheets.342 In addition to the abovementioned studies,
more complex Bi-based NPs have been reported as multifunctional
carriers that combine PAI with targeting, drug delivery, as well
as other imaging modalities.43,50,343,344 As for combined active
targeting and PAI, Yu et al.43 fabricated multifunctional BiNPs by
dissolving 1 mmol of Bi(III) acetate in 5 mL of OA for 1 h under
vacuum at 100 1C before additional mixing under dry nitrogen for
30 min. This mixture was added to 25mL of hot oleylamine (OAm)
at 260 1C and the reaction was carried out for 10 min (Fig. 18a1).
The initial size of the BiNPs was about 2 nm (Fig. 18a2) and
increased to ca. 12 nm after surface coating with PEG and further
conjugation of the LyP-1 peptide. The final formulation, termed as
Bi-LyP-1 NPs, exhibited excellent stability in different physiological
solutions and high accumulation in a 4T1 mammary gland breast
cancer tumor model (developed in the fat pad of the right legs of
mice) because of the tumor-homing LyP-1 peptide on their surface.
Light absorption in the second near-infrared (NIR-II) window also
rendered them with the ability of diagnostic imaging through a PA
modality. The PAI of tumor bearing mice that were intratumorally
(i.t.) injected with Bi-LyP-1 NPs (6 mg mL1, 30 mL) showed a high
PA signal intensity with an approximately 3.3-fold increase when
exposed to 700 nm laser irradiation (Fig. 18a3 and a4). The PAI
of mice injected with Bi-LyP-1 NPs through an intravenous
route (6 mg mL1, 200 mL) also demonstrated a time-dependent
lightening, in which the PA signal intensity of tumors increased
by ca. 3.6-fold at 8 h post-injection under 700 nm laser irradia-
tion (Fig. 18a3 and a5). Similar results were obtained with
800 and 900 nm laser irradiation, indicating the great promise
that BiNPs hold as highly competent CAs for PAI guided cancer
therapy under various NIR wavelengths.
As for combined drug delivery and imaging, Dou et al.50
reported Bi2S3 decorated graphene nanosheets that were func-
tionalized with PVP (termed as PVP–rGO/Bi2S3) and loaded with
DOX (Fig. 18b1 and b2). The nanocomposite possessed a very
high drug loading capacity of nearly B500% for DOX, which
was far beyond the loading values so far reported for nanosized
chalcogenides. This was mainly attributed to the large surface
area of rGO and the strong p–p stacking interaction between
the drug and rGO. Dual pH- and NIR-responsive drug release
along with PAI (Fig. 18b3–b5) were found to be the main
capabilities of this multifunctional nanocomposite. Combined
drug delivery and PAI have also been reported through the
synthesis of core–shell nanostructures. PEG modified meso-
porous silica-coated Bi NCs (Bi@mSiO2–PEG) is an example in
which the Bi core is fabricated via a chemical reducing
method.344 This nanohybrid had a final average size of ca.
73 nm and the thickness of mSiO2 was ca. 12 nm, while evenly
wrapping around the Bi NC and carrying DOX inside its
mesopores. In addition to the possibility of loading medicines
into the porous structure of the mSiO2 shell, Zheng et al.
239
found that SiO2 coating Bi2S3 can enhance the biocompatibility
and stability of the BiNPs in the harsh environments of the GI
tract when used orally as a probe for GI tract imaging.
Inspired by the photothermal properties of BiNPs, IRT imaging
using these nanostructures has also gained plenty of attention.
IRT is the science of converting infrared energy emitted from an
object to apparent temperature and presenting the result as an
infrared image. PVP-protected Bi nanodots have been used for
this purpose as an excellent IRT imaging contrast.335 The in vivo
IRT imaging capability of PVP–Bi nanodots was explored after IV
injection of the particles (20 mg kg1) into tumor-bearing mice.
After 24 h, the tumor model, established by subcutaneous injec-
tion of a U14 squamous cell carcinoma cell line in the left axilla
of Balb/c female mice, was irradiated with a 808 nm NIR laser
(1.3 W cm2), and an IR thermal camera was used for imaging
and measuring the temperature change of the tumors. While the
temperature of the control mice did not noticeably change,
the temperature of the tumor site increased after injection of
the PVP–Bi nanodots. This great result indicated that PVP–Bi
nanodots might be used as an excellent IRT CA for the real-time
monitoring of thermal dynamics during the PTT process.
Polydopamine (PD)/HSA/DOX coated Bi2Se3 (Bi2Se3@PD/
DOX/HSA) NPs have also been found to act as an excellent
contrast agent for IRT imaging.345 In vivo imaging using an IRT
camera revealed that all tumors inoculated by human cervix
HeLa adenocarcinoma cells demonstrate a green color before
irradiation (i.e., at 0 s). Similarly, upon 10 min irradiation, the
color of the free DOX and saline group barely changed. In
contrast, for the groups injected with Bi2Se3@PD/DOX/HSA
(25 mg kg1), the tumor turned red and became brighter upon
extended irradiation. The IRT camera showed that the tumor
temperature varies very little for the free DOX and saline groups
(the DT values of the free DOX and saline groups were 4.7 and
4.2 1C, respectively), whilst for the Bi2Se3@PD/DOX/HSA group,
the temperature greatly increased upon 10 min of laser irradia-
tion and high-contrast real-time IRT imaging of the tumor was
achieved. These examples show that intelligent designs com-
bining different functionalities of individual NPs will make a
great impact in the field of diagnostic nanomedicine.
6.3. Magnetic resonance imaging (MRI) and ultrasonography
(US)
In addition to the intrinsic properties of BiNPs for CT, PA, and
IRT imaging, their nanocomposites have also been investigated
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for MRI and US, broadening their applications in the imaging
field. MRI has been extensively applied for diagnostic imaging
due to its high spatial resolution, excellent contrast difference
of 3D soft tissues, and its noninvasiveness.346,347 Therefore, the
integration of iron (Fe), manganese (Mn), and Gd with BiNPs
enables the use of the NPs as a contrast agent for MRI. For
example, due to the presence of Mn, core–shell MnSe@Bi2Se3
has been applied as a MRI contrast agent.348 This nanostruc-
ture was fabricated via a partial cation exchange method, using
MnSe nanocrystals as a template in which the outer layer of Mn
was used for coating with the Bi2Se3 through ion exchange
and hydrophobic interactions before surface PEGylation. The
paramagnetic MnSe core offers contrasts for both T1- and
T2-weighted MRI, whereas the presence of the Bi2Se3 shell means
that the nanostructure can strongly absorb both X-rays and NIR
light, useful for CT and IRT imaging, as well as PTT. The corres-
ponding longitudinal relaxivity (r1) and transverse relaxivity (r2) of
MnSe@Bi2Se3–PEG were found to be 5.44 and 27.6 mM
1 s1,
Fig. 18 (a1) A schematic diagram showing the synthetic procedure of multifunctional Bi-LyP-1 NPs. (a2) A TEM image of the BiNPs before surface
coating with PEG and peptides. (a3) PA images of the tumor before and after the i.t. and intravenous administration of the Bi-LyP-1 NPs. (a4) PA signal
intensities from tumors obtained before and after the i.t. administration of the Bi-LyP-1 NPs at 700 nm. (a5) Signal intensities of tumors obtained before
and after (2, 4, and 6 h) the intravenous administration of Bi-LyP-1 NPs at 700 nm. Adapted and reprinted with permission from ref. 43 Copyright 2017.
(b1) An illustration of the synthesis procedure of the PVP–rGO/Bi2S3 nanocomposite. Thioacetamide (TAA), PVP and Bi(NO3)3 were mixed with GO and
heated for 2 h at 100 1C to produce PVP–rGO/Bi2S3. (b2) Elemental mapping of the nanocomposite (C: red; S: yellow; Bi: green), confirming the
successful formation of the final formulation. (b3) A plot of PA signal versus the concentration of the nanocomposite. (b4) Photoacoustic tomography
(PAT) phantom images of the aqueous dispersion of the nanocomposite with different concentrations, demonstrating its potential for PAI. (b5) The in vivo
PAT imaging of a tumor-bearing mouse after the i.t. injection of the particles. It is evident that no obvious signal was detectable by PAT imaging
before injection, while constant enhancement of the PAT signal was observed within a 40 min time period. Adapted and reprinted with permission from
ref. 50, Copyright 2013.
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respectively, comparable to the values of manganese oxide
NPs.349 In vivo MRI of 4T1 mammary gland breast cancer
tumor-bearing mice for T1-weighted MRI made the tumor
brighter, while the T2-weighted MRI showed negative contrast
in the tumor after the injection of NPs, demonstrating the
capability of MnSe@Bi2Se3–PEG to serve as a CA for use in both
T1- and T2-weighted MRI. Notably, the integration of T1- and
T2-weighted MR modes in a single nanoagent may potentially
enhance the ability of discriminating hypointense tissue in MRI
to overcome the intrinsic shortcomings of the T2-weighted
mode.350 In another example, Gd–PEG–Bi NPs were prepared
for high quality MRI/CT/PAI imaging. Gd was used to make the
system paramagnetic and PEGylation was used to improve the
blood circulation and biocompatibility of the nanocomposite.48
The r1 and r2 values of the Gd–PEG–Bi NPs were found to be
4.9 and 9.6 mM1 s1, respectively, which are comparable to
Magnevist, a commercially available nanoagent contrast. In
addition, in vivo imaging lasted for 3 h post-injection, which
is longer than the 30 min time window of imaging using
Magnevist.351 Naha et al.260 also reported the synthesis of
dextran-coated Bi–iron oxide NPs, in which the iron oxide
serves as a contrast agent for T2-weighted MRI, while Bi endows
this nanocomposite with the ability to act as a CT contrast
agent. Herein, it was shown that the MRI contrast decreases
with the enhancement of the Bi content in the nanohybrid.
Therefore, it was assumed that Bi-containing MRI CAs are not
powerful enough to be used for single imaging modality, but
instead effective as a dual- or multi-modality CA.
US is another modality, which has been combined with the
imaging and therapeutic potentials of BiNPs through the formation
of novel nanocomposites. For example, Bi2S3-embedded poly(lactic-
co-glycolic acid) (PLGA) nanocapsules have been synthesized to
achieve excellent US performance due to the presence of PLGA,
which enhances the contrast of the imaging.209,352,353 The PLGA
shell efficiently increases the US energy deposition, thus enhancing
the HIFU therapeutic efficacy. The embedded Bi2S3 NPs enabled
highly improved RT. The Bi2S3–PLGA NPs demonstrated good
performance in real-time ultrasonography-guided HIFU therapy,
determining the location of the tumor, while monitoring the
treatment process.
All in all, these examples provide primary knowledge for the
further investigation and design of multimodal CAs based
on BiNPs as their intrinsic CT, PA and IRT imaging modalities
can be combined with other imaging techniques through the
fabrication of novel nanocomposites.
7. Bi nanoplatforms for cancer therapy
Cancer therapy can be considered a major role of BiNPs in
biomedicine. To date, various types of therapeutic approaches,
such as chemotherapy, PTT, RT, HIFU, photodynamic therapy
(PDT), and immunotherapy, have been able to successfully
enter into the clinic either as mono- or multi-therapies. Never-
theless, it is believed that there is a long way ahead for the
discovery of novel anticancer agents and therapeutic strategies
in laboratories for future clinical translation. Various nano-
materials have been introduced for this purpose. In this section,
we describe BiNPs as one of those materials, which have
demonstrated huge potential for efficient cancer treatment
through both mono- and multi-therapy.
7.1. Photothermal monotherapy of cancer by Bi
nanoplatforms
Thermotherapy is a type of cancer treatment in which the tumor
tissue is exposed to a fatal temperature to damage proteins and
structures within cells and shrink tumors. The heat tolerance of
tumor tissues is lower than that of normal tissues and the
damage induced by hyperthermia is irreversible because of
weakened cell membranes and protein denaturation. NIR-laser
mediated hyperthermia is a common method of PTT, which is
believed will revolutionize the field of cancer therapy in the
near future.37,46 Tumor tissue absorbs the light energy of the
NIR laser and converts it to localized heat for the ablation of
malignant cells.354–358 NIR-mediated PPT is desirable due to
light penetration into the skin by up to several centimeters,
since water, lipids, and the hemoglobin of tissues exhibit
negligible absorption of light in the IR region, ranging from
700 to 1300 nm. BiNPs have recently gained considerable
interest as promising nanoagents for cancer PTT, as a result of
their strong absorbance in the NIR region, high photothermal
conversion efficiency, and also high biosafety.38,359,360 For
example, the photothermal conversion efficiencies of Bi2S3/
Cu2S/Cu3BiS3 composites,
361 Bi2S3–Au heterojunction NRs,
362 and
hydrophilic flower-like Bi2S3 NPs
358 were found to be 43.8%,
51.06%, and 64.3%, respectively. PVP–Bi2Se3 nanosheets with a
diameter of 31.4 nm and a thickness of 1.7 nm have also been
shown to have an extinction coefficient of 11.5 L g1 cm and
photothermal conversion efficiency of 34.6% at 808 nm, which
are highly desirable for the eradication of cancer tissue
in vivo.363 Bi2S3 nanorods have been reported as a PTT
platform38 in which the hyperthermia-induced killing of 4T1
cancerous cells was followed by no considerable sign of pul-
monary metastasis in the nanomaterial-based PTT group. In
contrast, a large number of metastasis sites were found in the
lungs of the control groups. This observation originated from
the fact that nanomaterial-based PTT may be beneficial for
triggering immunological responses against tumor cells in the
body, thus contributing towards inhibiting metastasis.364–367
Since a great number of BiNPs often fail to reach cancer tissue
and are rapidly eliminated from the body, cell-mediated
NP-delivery has been proposed to improve the therapeutic
efficiency of BiNPs through their higher transport to tumor
tissue. Macrophages with innate phagocytotic capability were
used for the loading and delivery of Bi2Se3 nanosheets
368 with a
size of 84.0  11.3 nm. Macrophages were shown to uptake
nanosheets after 24 h of exposure in a dose-dependent manner
(Fig. 19a1 and a2). Bi and Se biodistribution in mice revealed
that for bare Bi2Se3 nanosheets, a large concentration of Bi and
Se accumulates in the liver and spleen, but a small amount in
an epithelial adenocarcinoma MCF-7 breast tumor model. This
is probably because the tumor uptake of Bi2Se3 nanosheets is
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dependent on: (1) their low passive accumulation in the tumor,
which relies on the size, shape, coating, and surface charge of
the nanomaterials, and (2) the difficulty in overcoming the
hypoxia-associated drug delivery barrier.369,370 In contrast, the
Bi2Se3-laden-macrophages illustrated a much higher targeting
efficiency with Bi and Se concentration in the tumor, being 3- to
4-fold higher than those of the Bi2Se3 group. After PTT, the
group treated with Bi2Se3-laden-macrophages illustrated com-
plete tumor ablation with overall survival of 100% after up to
45 days of screening post-irradiation without tumor recurrence.
In the animal group treated with the bare Bi2Se3 NPs, tumor
growth was partially inhibited due to the PTT effect of Bi2Se3 in
the first 4 days, but fast tumor growth was observed thereafter,
and all the mice died within 32 days.
In addition to the delivery of BiNPs by live cells, cell-
membrane-camouflaged BiNPs can be considered a perfect
biomimetic nanosystem with powerful advantages that can
hardly be achieved with any other type of physical or chemical
surface modification. It has been proven that the a4 integrin of
the macrophage membrane can interact with the vascular cell
adhesion molecule-1 (VCAM-1) of the cancer cells, enabling
active targeting of the lung metastasis of breast cancer.371
Therefore, it was assumed that the combination of BiNPs
with macrophage membrane will not only provide high blood
retention capacity and excellent immune escaping properties,
but also active targeting ability. In this context, macrophage
membrane-camouflaged quercetin (QE)-loaded hollow Bi2Se3
NPs (M@BS-QE; Fig. 19b1 and b2) with hyperthermia triggered
drug release performance were developed for targeted inhibi-
tion and treatment of breast cancer and lung metastasis of
breast cancer.372 In addition to the affinity of macrophages
to the VCAM-1 of cancer cells, secretion of C–C chemokine
ligand 2 (CCL2) from breast tumors and stromata is a proven
mechanism that facilitates the recruitment of C–C chemokine
receptor 2 (CCR2)-expressing macrophages to the cancer cells.
Therefore, this study was aimed at benefitting from both these
phenomena, using the macrophage membrane as the outer
shell of the Bi2Se3 NPs. These NPs were found to considerably
sensitize breast cancer cells to PTT (Fig. 19b3). Therefore,
combining this therapeutic modality with excellent immune
evading properties, CCL2/CCR2 recruitment ability, and
a4/VCAM-1 identification ability of the M@BS-QE NPs led to
Fig. 19 (a1) The uptake of Bi2Se3 nanosheets by macrophages. Bright-field images of macrophages before (left) and after (right) the uptake of the Bi2Se3
nanosheets. The change in color within the cells confirmed the presence of nanosheets inside the cells. (a2) A quantitative determination of Bi2Se3
nanosheet uptake by macrophages, showing a concentration dependent trend. Adapted and reprinted with permission from ref. 368, Copyright 2017.
(b1) An illustration of the synthetic procedure for biomimetic M@BS-QE. (b2) TEM images of M@BS-QE. The cell membrane is shown between the two
red arrows. (b3) An evaluation of the photothermal destruction of 4T1 cells after treatment with an NIR laser at 808 nm in the presence of Bi2Se3 NPs.
(b4) Histological examination of metastatic lesions in lung tissue. The metastatic lesions are stained with dark nuclei. The PBS, free QE, and BS-QE NP
treated groups exhibit plenty of dark areas in the lung, but metastatic lesions were barely visible in the M@BS-QE group, implying the promising anti-
metastatic performance of the M@BS-QE NPs. Adapted and reprinted with permission from ref. 372, Copyright 2018.
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the outstanding suppression of breast cancer lung metastasis
(Fig. 19b4).
Coating the BiNPs with biocompatible proteins/polymers and
active targeting by antibodies are other strategies to improve the
PPT of the cancer.373,374 In a study byWang et al.,373 protein coating
was performed during the fabrication of Bi2S3 NPs (Fig. 20a). An
aggregation induced emission dye (PhENH2) was first incorporated
in the hydrophobic domains of BSA. Next, the BSA–PhENH2
complexes were coordinated with Bi3+ ions under acidic conditions
before quickly increasing the pH to 12 to form BSA–PhENH2-coated
Bi2S3 NPs. PhENH2 was used for the fluorescence imaging of the
fabricated BSA–PhENH2–Bi2S3 NPs, which exhibited high colloidal
stability and high PTT effect upon 808 nm laser irradiation.
Importantly, BSA not only played a significant role in improving
the water dispersity of the particles and as a stabilizer of the
fluorescent PhENH2 dye, but also its cysteine groups were a
sulfur precursor for the further preparation of Bi2S3 NPs. Bi
(III)
cations are prone to hydrolysis to form Bi(OH)3 in an acidic
environment. This study revealed that the BSA-mediated bio-
mineralization of the BiNPs is an efficient and straightforward
strategy, owing to the abundant amino acid residues on BSA that
facilitate the binding of Bi3+ ions to BSA and improve their
stability in an acidic environment. For targeted phototherapy,
CD47-targeted PEGylated Bi2Se3 NPs were constructed following
the protocol shown in Fig. 20b1. Anti-CD47 antibody (Ab) con-
jugated PEG–Bi2Se3 (Ab–PEG–Bi2Se3) NPs were shown to target
tumor tissue and also increase the phagocytosis of cancer cells
using macrophages to accelerate the effect of the PTT. CD47 is
Fig. 20 (a) A schematic representation of the fabrication process of BSA–PhENH2–Bi2S3 NPs. Adapted and reprinted with permission from ref. 373,
Copyright 2017. (b1) A schematic depiction of the fabrication of Ab–PEG–Bi2Se3 NPs. (b2) A schematic illustration of the proposed anticancer mechanism
of Ab–PEG–Bi2Se3 through PTT, with the inhibition of CD47–SIRPa interactions, secretion of stimulatory cytokines, and macrophage-mediated
phagocytosis of cancer cells. (b3) The temperature of Ab–PEG–Bi2Se3 suspensions at different concentrations over a 10 min time period of irradiation
with an NIR laser. (b4) A comparison of the heating and cooling curves of an Ab–PEG–Bi2Se3 suspension (200 mg mL
1) and pure DI water. Adapted and
reprinted with permission from ref. 374, Copyright 2019.
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an overexpressed protein inmost tumors that limits themacrophage
phagocytosis effect by interacting with macrophage signal-regulated
protein a (SIRPa).375 The developed NPs can block the crosstalking
between CD47 and SIRPa as a ‘‘do not eat me’’ signal that inhibits
the attack of macrophages, which accounts for 30–50% of the cells
in the tumor mass.376 Selective accumulation of the Ab–PEG–Bi2Se3
NPs in a 4T1 mammary gland breast cancer tumor model, which
was developed in female BALB/c mice, promoted the photothermal
performance through stronger NIR absorbance, while enhancing
macrophage-mediated phagocytosis of cancer cells via the inhibition
of CD47–SIRPa affinity, as well as hyperthermia-induced release
of stimulatory cytokines, such as IL-1b and tumor necrosis factor
alpha (TNF-a) from the tumor cells. This synergized the cancer
suppression effect of the PTT (Fig. 20b2–b4) through the local
stimulation of macrophages, NK cells and T lymphocytes against
cancer cells via secreted inflammatory cytokines.377–380
In all of the above examples, a very high power laser was
needed to heat the tumor to over 50 1C and achieve thorough
ablation of the cancer cells. The induced hyperthermia to a
tumor-killing temperature inevitably harms the surrounding
healthy tissues. This drawback might limit the clinical applica-
tion of PTT. Alternatively, mild hyperthermia of the cancer
tissue at a relatively low level (e.g., 45 1C) is desirable; however,
its killing effect is concerning and probably far from sufficient.
Therefore, combining other therapeutic strategies for hyperthermia
treatment under mild PTT have been proposed.381 For example,
NIR-triggered nitric oxide (NO) releasing Bi2S3 NPs were con-
structed for NO-sensitized mild PTT. N,N0-Di-sec-butyl-N,N0-
dinitroso-1,4-phenylenediamine (BNN), which is a hydrophobic
NO donor, was loaded on the surface of Bi2S3 NPs (Fig. 21a and
b).382 Since BNN is stable below 60 1C, unexpected NO release
under physiological conditions was avoided and just the high local
temperature on the surface of Bi2S3 NPs (induced by NIR laser)
triggered the decomposition of BNN and NO release (Fig. 21c).
Therefore, upon NIR irradiation at 808 nm, mild PTT and
on-demand NO release were simultaneously achieved to efficiently
kill BEL-7402 hepatocellular carcinoma cells in vitro and also
in vivo in female BEL-7402 tumor bearing mice (Fig. 21d and e).
This strategy prohibits unwanted NO release in the systemic
circulation and prevents its unexpected side effects. Instead, NO
circumvents the heterogeneous heating distribution in the cancer
tissue through the induced impairment of the autophagic
self-repairing ability of cancer cells, which can subsequently
accelerate the apoptotic shrinkage of the tumor tissue.
7.2. Radiation monotherapy of cancer by Bi nanoplatforms
RT is an important modality for cancer suppression that
most often employs X-ray beams of intense energy to damage
the genetic components of cancer cells. External beam therapy
that uses a machine outside of the body to aim high-energy
beams at a precise point on the body is the most common
method used for RT. However, brachytherapy is another avail-
able approach in which radiation is targeted inside the body.
Despite a plethora of recent attempts on RT, this method fails
to fully eradicate tumors due to the (1) radiation insensitivity of
some tumors due to their hypoxic nature, acidosis, and dense
extracellular matrix, as well as (2) insufficient transfer of energy
needed for ionization of the atoms that make up the DNA chain
of the cells.52,209,383 In both scenarios, the production of free
radicals in the cells is not high enough to destroy all cancer cells.
Therefore, it is rather urgent to improve the efficiency of cancer
radiotherapy via concentrating the radiation energy within the
cancer tissues, while reversing their hypoxic microenvironment.384
Using heavy metal nano-radiosensitizers is a helpful approach to
enhance the therapeutic efficiency of RT without increasing radia-
tion doses to dangerously high levels that can non-selectively affect
the normal function of surrounding tissues.385 BiNPs are used for
this aim because of their strong photoelectric absorption and high
generation of secondary electrons under radiation exposure.386–389
Huang et al.353 constructed a brachytherapy platform based on
Bi2S3 encapsulated PLGA nanocapsules (Bi2S3@PLGA) using a
water/oil/water (W/O/W) emulsion approach. Bi2S3 was used as a
radiation sensitizer after exposure to gamma or X-ray irradiation
and caused the death of PC3 prostate cells in vitro (200 mg mL1)
via the induction of DNA breakage. The PLGA capsules could
be used as a CA for US, by which the radiation sources of
brachytherapy could be guided into the desired position.
In vivo findings in nude mice bearing a PC3 prostate carcinoma
tumor xenograft demonstrated ca. 30% reduction in the tumor
volumes by the BiNP mediated RT in comparison to the group
that did not receive the NPs. Besides this, the immunohisto-
chemical staining of the Ki67 protein of the tumor cells showed
an obvious reduction in its expression in the NP treated group
exposed to RT, while the other groups did not exhibit this.
Nevertheless, the modulation of the abnormal tumor micro-
environment through oxygenation was proposed as a useful
strategy for further enhancement of the RT efficacy.369 For
example, BSA-coated Bi2S3–MnO2 nanocomposites were found
to be capable of modulating hypoxic conditions in the tumor to
enhance the efficacy of RT.390 After accumulation in the tumor,
endogenous elevated H2O2 at the tumor site reacted with MnO2
to generate oxygen, leading to diminished hypoxia-associated
resistance to RT.
In addition to the oxygen-deficient microenvironment of
the tumor, which reduces the effect of RT, the abundance of
antioxidants in the cancer tissue is another feature that may
protect them against the damage from RT via the quenching
of excess free radicals.391 For example, glutathione (GSH) is
nearly B4-fold higher in cancer cells compared to in normal
cells392–394 and can decrease radiotherapeutic efficiency via its
radical scavenging effect on ROS.395,396 In a pioneering and
novel approach, Zhou et al.23 investigated the radiosensitizing
effect of a nanomaterial composed of two high-Z elements, i.e.,
Bi and W to achieve a better outcome for RT. They synthesized
bismuth heteropolytungstate (BiP5W30) coupled with reduced
graphene oxide (rGO) and surface modified with PVP (termed
as PVP-PG) (Fig. 22a1). The hybrid composed of BiP5W30
nanoclusters and rGO was prepared via an electrochemical
reduction (ECR) process. The BiP5W30 was found to be capable
of depleting GSH by virtue of its unique electron structure and
multi-electron properties meaning that it can catalyze the
decomposition of H2O2 to OH to enhance ROS generation
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upon treatment with X-ray radiation. The rGO was found to
further improve the radiocatalytic activity through enhanced
electron–hole separation, while PVP rendered the NPs with
exceptional stability in biofluids, with desirable biocompatibility.
Although the photocurrents generated from both BiP5W30 and
PVP-PG showed rapid response upon X-ray on/off switching,
which is an indication of electron–hole separation, PVP-PG was
able to generate a 4-fold higher photocurrent than that of the
BiP5W30 nanoclusters (Fig. 22a2). In fact, the presence of rGO
more efficiently induced the separation of radiogenerated
electron–hole pairs because of its two-dimensional planar
structure that facilitates electron transportation.397 These
radiogenerated electrons and holes were able to initiate the
chemical reactions due to the robust photooxidative ability of the
holes and photoreductive ability of the electrons,398 resulting in
enhanced generation of hydroxyl radicals within a human cervix
adenocarcinoma cell line (HeLa cells) upon X-ray irradiation
(Fig. 22a3). In addition, the rGO was used for the absorption
of NIR light and heat production as a mechanism confirmed to
overcome the hypoxic microenvironment of the tumor and
synergize the antitumor effects of RT, resulting in very effective
suppression of tumor size in vivo (Fig. 22a4). A similar concept
using two high-Z elements in a single NP was also employed
for the fabrication of PVP–Bi2WO6 nanoplates that exhibited
very high X-ray energy deposition performance, favorable photo-
current and photocatalytic-like radiocatalytic activity upon treat-
ment with X-rays. This resulted in the effective separation
of electron/hole (e/h+) pairs and subsequently promoted the
generation of cytotoxic OH (Fig. 22b1), confirmed by the
detection of a 20,70-dichlorofluorescein (DCF) fluorescence
signal in live cells using confocal laser scanning. It was obvious
that the green fluorescence signals were highly emitted from
HeLa cells treated with both PVP–Bi2WO6 nanoplates and
X-rays, whereas only weak fluorescence signals could be detected
in the cells treated with PVP–Bi2WO6 nanoplates or X-rays alone.
A clonogenic assay on human cervix adenocarcinoma cell line
Fig. 21 (a) A schematic representation of the synthetic procedure and NIR-responsive NO release properties of BNN–Bi2S3. A synergistic mechanism
involving mild PTT and NO in cancer therapy is shown to be a very favorable approach for avoiding damage to healthy tissues. (b) A TEM image of Bi2S3 NRs.
(c) The generation of NO from the BNN–Bi2S3 nanocomposite under 808 nm NIR laser irradiation with different power densities. (d) In vitro synergistic
effects of mild PTT and NO achieved via the laser irradiation of the BNN–Bi2S3 nanocomposites. The cell viability of BEL-7402 cells was decreased more for
BNN–Bi2S3 treated samples compared to ones treated with Bi2S3 at different concentrations under 808 nm laser irradiation. (e) The in vivo tumor volume of
different groups of mice over fifteen days after various treatments. Adapted and reprinted with permission from ref. 382, Copyright 2019.
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(HeLa cells) confirmed the radiosensitizing effect of the PVP–
Bi2WO6 nanoplates via a high amount of ROS generation. The
cells were treated with the NPs (100 mg mL1) for 6 h before
washing and exposure to X-rays (50 kV, 75 mA) for 30 s before
cell culturing and staining with Giemsa dye to visually count
the number of cell colonies. As can be observed in Fig. 22b2,
Fig. 22 (a1) The synthesis procedure of PVP-PG. (a2) X-ray induced photocurrent with BiP5W30 clusters and PVP-PG through the on/off switching of
X-ray irradiation. (a3) The relative content of hydroxyl radicals in HeLa cells after different treatments. (a4) Digital images of the dissected tumors of each
group. Adapted and reprinted with permission from ref. 23, Copyright 2019. (b1) Fluorescence images of ROS generation in HeLa cells treated differently
and stained using Hoechst 33342 and DCFH-DA. (b2) Digital photographs of the colony formation of HeLa cells (1) without any treatment, and after
treatment with (2) 100 mg mL1 PVP–Bi2WO6 nanoplates, (3) X-rays and (4) PVP–Bi2WO6 + X-ray irradiation (50 kV, 75 mA, 30 s). Adapted and reprinted
with permission from ref. 402, Copyright 2019. (c1) A TEM image of the Au–Bi2S3 nanocomposite. (c2) Fluorescence images of HeLa cells after different
treatments and staining with Hoechst 33342 (blue) and DCF (green) for the imaging of nuclei and free radical generation, respectively. (c3) A schematic
demonstration of the plausible mechanism involved in enhanced free radical generation via an X-ray-induced catalytic progress by Schottky-type
Au–Bi2S3 heterostructures When Bi2S3 and Au come into contact, electrons from Bi2S3 transfer to Au at the interface until equilibrium is reached between
EFermi,Bi2S3 and EFermi,Au, resulting in new EFermi generation. This process leads to the formation of a positive charge layer at the surface of Bi2S3 and the
accumulation of negative electrons on the surface of Au, leading to the deformation of the band structure between Au and Bi2S3, where the surface
potential barrier, known as the Schottky barrier is formed. Adapted and reprinted with permission from ref. 403, Copyright 2019.
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the control and Bi2WO6 nanoplate-treated groups (1 and 2)
produced more colonies than those of the X-ray (3) or Bi2WO6 +
X-ray (4) treated groups. According to all of the above examples,
development of oxygen-independent RT approaches that over-
come the hypoxia of the tumor tissue is currently the key for
further development of novel multifunctional radiosensitizers.
PVP-modified Schottky-type heterostructured Au–Bi2S3 NPs
(Fig. 22c1) are another example material that can deposit a
high radiation dose within tumors in the form of high energy
electrons and efficiently eradicate cancer without suffering
from the oxygen-dependent radio-sensitizing behavior of the
NPs in hypoxic tumors. The generation of free radicals in HeLa
cells was evaluated by employing 20,70-dichlorofluorescin dia-
cetate (DCFH-DA) as a probe for the detection of free radicals.
The green fluorescence of DCF was then detected, showing
no signal in the Au–Bi2S3 and NIR treated groups, a very weak
signal in the X-ray and Au–Bi2S3 + NIR groups, and a very strong
signal in the Au–Bi2S3 + X-ray and Au–Bi2S3 + NIR + X-ray groups
with the latter showing the biggest effect on ROS generation
(Fig. 22c2). This feature of Schottky-type heterostructured
Au–Bi2S3 is associated with the generation of a Schottky barrier
between the metal, Au, and semiconductor, Bi2S3, which can trap
the electrons generated by the X-ray treatment and transfer them
to the Au, resulting in the prevention of the recombination of
the electron–hole pairs (Fig. 22c3).399–401 Thereafter, due to the
matched potential between the conduction band of the Bi2S3
NPs and overexpressed H2O2 within the tumor, the Au–Bi2S3
nanocomposite induces the decomposition of intracellular H2O2
into highly toxic OH for selective killing of HeLa cells.
7.3. Combined cancer therapy and theranostics based on
BiNPs
Despite the great efforts devoted to cancer monotherapy over
the past decades, efficient eradication of tumors at an early
stage remains a big challenge. Most tumors are not detected
until they become large in size, increasing the risk of poor
therapeutic outcome and metastasis. An alternative approach is
combining more than one therapeutic method with diagnostic tools
to overcome the shortcomings of the individual therapies.404,405
The simultaneous use of imaging modalities and multi-therapy
requires versatile nanotheranostic agents.209 In this context,
BiNPs were proposed, owing to their diverse applications, such
as CT imaging, PAI, PTT, and RT.406 For example, ultrasmall
BSA stabilized Bi2Se3 nanodots have exhibited a high photo-
thermal conversion efficiency (Z = 50.7%) for PTT, while serving
as PAI and CT multimodal imaging-guided synergetic sensiti-
zers for radiotherapy.407 The average size of the NPs was
2.7  0.3 nm and they were simply synthesized through the
reaction of bismuth chloride with hydroxyethylthioselenide in
aqueous solution under ambient conditions. Most studies have
reported the synthesis of BiNPs in hydrophobic organic solvents
to avoid the fast hydrolysis of Bi3+. However, these NPs are large
in size and post synthetic surface modification was needed to
make themwater soluble. Their large size might also lead to long
metabolism and inducemore side effects.252,408 Therefore, in the
abovementioned study, the advantage of preparing hydrophilic
and biocompatible Bi2Se3 BiNPs by dissolving water soluble
bismuth salts in an acidic solution is highly significant as it
could prevent the hydrolysis of Bi3+ ions, leading to the produc-
tion of ultrasmall NPs.
The intrinsic PTT, RT, CT, and PAI potentials of BiNPs have
also been combined with other imaging modalities or therapeutic
strategies, such as MRI, chemotherapy and immunotherapy,
to develop novel theranostics. For example, monodisperse
Gd2O3/Bi2S3 hybrid nanodots (Gd/Bi-NDs) were prepared for
simultaneous CT, PAI, MRI and PTT.409 Bi(NO3)3 and GdCl3
were mixed with BSA in water under vigorous agitation before
adjusting the pH to 12. Under basic conditions, the abundant
active groups of the albumin molecules were found to efficiently
bind to the metal ions of Bi3+ and Gd3+ to generate crystal nuclei.
Numerous cysteine residues were also released to act as a precursor
for the nanoprecipitation of Bi2S3 nanocrystals. Nanoprecipitation
of the Gd3+ ions also occurred under basic conditions as a result of
their binding to albumin molecules and subsequent formation of
Gd2O3 nanocrystals through the reaction of hydroxyl groups with
Gd3+ ions (Fig. 23a1). In addition to NIR fluorescence imaging that
showed the in vivo retention behavior of the Cypate-labeled NPs in
epithelial 4T1 mammary gland tumors for nearly 48 h (Fig. 23a2),
PAI, MRI, and CT imaging were monitored with maximum PA and
MR intensity at 12 h and efficient CT contrast during 2 h post-
injection (Fig. 23a3–a5). The relaxivity of Gd/Bi-NDs was found
to be around 26.8  103 m1 s1, which is eight-fold higher
than that of gadolinium–diethylenetriamine pentaacetic acid
(Gd–DTPA, 3.2  103 m1 s1). The CT contrast of these NP is
also ca. 2.5-fold higher than that of Iopromide. Efficient cellular
uptake, high tumor accumulation, favorable in vivo clearance,
negligible acute toxicity, and effective photothermal tumor
ablation without recurrence makes these monodisperse multi-
component nanoagents highly promising as efficient cancer
theranostic agents.
Combined phototherapy and immunotherapy using BiNPs is
another novel approach recently highlighted for multi-therapeutic
cancer ablation. Song et al.410 prepared immune-adjuvant
encapsulated Bi2Se3 nanocages for photothermal-improved
PD-L1 checkpoint blockade metastasis therapy. As shown in
Fig. 23b, MnSe nanocubes were used as a template to fabricate
Bi2Se3 nanocages (NCs). First, manganese acetate tetrahydrate
was added into a mixture of 1-octadecene, oleylamine and oleic
acid at room temperature, followed by heating at 120 1C for
60 min to obtain solution no. 1. Next, selenium was dispersed
in a solution of oleylamine and 1-dodecanethiol, followed by
its addition into solution no. 1 and was held at 220 1C for 2 h.
After cooling to 50 1C, a solution of 1-octadecene containing
bismuth neodecanoate was added under a constant flow of
nitrogen and the mixture was heated to 180 1C for 0.5 h under
vigorous stirring. The solution was then cooled down to room
temperature and oleylamine coated Bi2Se3 NCs were collected
by centrifugation for further decoration with PEG (termed as
NC-PEG). Imiquimod (R848), a toll-like receptor-7 agonist, was
loaded into the NCs to generate strong anti-cancer immune
responses by NC-PEG/R848. NIR mediated PPT using this
immunogenic NP not only ablated the light-exposed cancer
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tissue, but also induced strong anti-cancer immunity to sup-
press the growth of a distant secondary tumor through the
increased secretion of inflammatory cytokines, including TNF-
a, interferon g (IFN-g), and IL-12p40. Co-Administration of this
formulation with an anti-PD-L1 antibody further silenced the
immune resistance based on a PD-L1 checkpoint blockade to
suppress the primary tumor, considered as a synergistic
approach for the inhibition of tumor metastasis. In addition
to these examples, there are other studies on combined therapy
with BiNPs, which are summarized in Table 3, indicating the
potential of these nanomedicines for future investigation and
creation of versatile multifunctional theranostics.
8. Bi-Based biosensors
Biosensors are analytical devices that translate amounts of
biochemical substances into a measurable signal, which is
directly related to the level of the analyte. The main compo-
nents of biosensors include a bioreceptor that identifies the
analyte and generates a signal, a transducer that converts
signals into quantifiable and user-friendly electronic pulses,
and a reader device to represent the signal in a displayable
format.425 Electrochemical and photoelectrochemical (PEC)
technologies (converting photoirradiation to electrical signals
(current or potential)426,427 are the main detection methods
used in the development of biosensing devices for drug dis-
covery, food safety, environmental monitoring, and more
importantly medical diagnostics through the detection of var-
ious analytes within complex body fluids (e.g. saliva, blood,
urine).425,428 Among the various types of biosensors, nano-
based ones exhibit great promise for meeting the demands of
clinical diagnosis due to their attractive features of a high
surface area, high stability and sensitivity, high selectivity,
simplicity of construction, reproducibility, speed of response
and low cost of analysis.425 Different types of nanomaterials,
such as carbon-based nanostructures, metal NPs, magnetic
NPs, and polymeric NPs have been utilized as both bioreceptors
and transducers to improve the performance of electrochemi-
cal, optical, mass-based, or calorimetric sensors due to the
desirable strength of the signal detection.429,430 Various types
of Bi-based nanomaterials, such as its metallic forms, binary
Fig. 23 (a1) A schematic illustration of Gd/Bi-NDs nanodots synthesized through separate nanoprecipitation reactions in a single albumin solution and a
corresponding TEM image of the NPs. (a2) In vivoNIR fluorescence imaging of mice injected with Cypate-labeled Gd/Bi-NDs and free Cypate at a dose of
20 mmol kg1 Bi. (a3) In vivo PAI of xenografted tumors from mice injected with Gd/Bi-NDs at a dose of 20 mmol kg1 Bi over 24 h post-injection. (a4)
In vivo MRI of mice injected with Gd/Bi-NDs and Gd–DTPA at a dose of 20 mmol kg1 Gd over 24 h post-injection. (a5) In vivo CT imaging of mice i.t.
injected with Gd/Bi-NDs and Iopromide at a dose of 125 mmol kg1 Bi over 2 h. Adapted and reprinted with permission from ref. 409, Copyright 2018.
(b) A schematic illustration of the synthesis procedure of Bi2Se3 NC-PEG/R848. Reproduced from ref. 410, Copyright 2019.
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oxides (Bi2O3) and multicomponent oxides (e.g., BiVO4),
selenides (Bi2Se3), sulfides (Bi2S3) and oxyhalides (BiOX) have
newly emerged for use in biosensing applications.427 The
unusual performance of BiNPs as a biosensor relies on their
unique physicochemical properties that include high electrical
resistance and low thermal conductivity, high surface-to-
volume ratio, high surface free energy, excellent visible-light
activity, and favorable properties for biomolecule adsorption.431,432
In addition, Bi materials are non-toxic, biocompatible, chemically
inert, highly stable, environmentally friendly, and provide high
resolution of the voltammetric responses and desirable limit of
detection (LOD), while their synthesis is usually easy and
affordable.431,432 Due to the above-described properties, Bi is
considered as an alternative to toxic sensing electrodes, such as
metallic mercury, since various forms of its composites can be
simply prepared, mainly for electrochemical and PEC biosensing
using different metals.427,433–435 Electrodes incorporating Bi in
the bulk state,436,437 BiNPs of various shapes and sizes,433,438–444
and Bi film electrodes (BiFEs)445–448 have been developed for the
determination of various analytes with high sensitivity and
low background signal and their general applications have
previously been well-reviewed.427,431,449,450 Herein, our focus will
be on the biomedical applications of sensors developed using
different chemical forms and shapes of BiNPs and BiFEs.
8.1. Bismuth oxides (BiOx) for biosensing
BiOx materials possess interesting physical properties for bio-
sensing technology, recognized as p-type electronic semi-
conductors with a large energy band-gap of around 2.1 eV, a
high refractive index, favorable dielectric permittivity, photo-
conductivity and photoluminescence properties.451–453 As a
result of their chemical inertness and in vivo biocompatibility,
BiOx materials have recently been proposed for gas sensing,
as a coating for photovoltaic cells, as well as in biosensor
fabrication.454,455 Nanosized BiOx (nano-BiOx) shows the pro-
minent features of a high surface area, high surface free energy,
and electrochemical stability, which plays meaningful roles in
analyte adsorption and detection at low concentrations. These
physical properties have resulted in the development of BiOx
materials for use in glucose sensing,433 DNA hybridization,442
and H2O2 detection.
441 For example, Ding et al.433 developed a
nanostructured amperometric glucose biosensor based on
spreading a solution mixture of glucose oxidase (GOD) and
polycrystalline nano-BiOx (composed mainly of BiOx nanorods
and nanosheets) onto a platinum disk electrode, followed by
drying and 15 min of treatment using saturated glutaraldehyde
vapor in order to induce the chemical cross-linking of the
entrapped enzyme molecules on the surface of the electrode.
Then, the amperometric measurement of glucose levels was
achieved by the GOD mediated oxidation of b-D-glucose to
gluconic acid and hydrogen peroxide in the presence of O2.
The GOD/nano-BiOx electrode was finally able to oxidize the
enzymatically generated hydrogen peroxide at 0.5 V. Linear
measurement of glucose levels was observed over a concen-
tration range of 1  106 to 1.5  103 M with a detection limit
of 4  107 M and a sensitivity of 51.0  0.4 mA M1 cm2.
This achievement is associated with the photovoltaic effect of
the NPs, which assists the enzymatic reaction through the
catalysis of oxidation/reduction reactions. This biosensor
exhibited favorable thermodynamic stability and life span due
to the protective effect of the BiOx matrix on the degradation
of GOD enzyme. This can be explained by partial enzyme
embedding or encapsulation in nano-BiOx during the proce-
dure of enzyme immobilization, resulting in improved thermal
resistance, which might also explain the extended storage
stability of over 2 months.
To enhance the capacity of converting photoirradiation into
an electrical signal in PEC biosensors and overcome the
high toxicity, easy photo-bleaching, and the narrow optical
response range of the classical semiconductor group (II–VI)
nanohybrids,427,456 multicomponent BiOx and BiOX (X = F, Cl,
Br, and I), such as bismuth oxybromide (BiOBr),457 bismuth iodide
oxide (BiOI),202 Bi2O3,
458 Bi vanadate (BiVO4),
201,459 BiFeO3,
460 and
perovskites members like Bi2WO6
461,462 have drawn significant
attention, particularly in the design of PEC immunosensors.
They possess superb properties under visible light irradiation,
such as high chemical stability, low toxicity, a large energy
band gap, high refractive index, dielectric permittivity, high
oxygen–ion conductivity, and pronounced photoconductivity
and photoluminescence properties.448,452 Zhu et al.462 fabri-
cated Bi2WO6 nanosheets to be incorporated into an organic–
inorganic heterojunction (interface that occurs between two
layers or regions of dissimilar crystalline semiconductors) of a
polypyrrole@Bi2WO6-based electrode, yielding a sensitive PEC
immunoassay for the early detection of creatine kinase-MB,
present a few hours after a heart attack. Fan et al.457 developed
an ultrasensitive label-free immunosensor based on a bismuth
oxybromide/silver sulfide (BiOBr/Ag2S) composite with high
visible-light PEC activity for the detection of insulin (Fig. 24a).
An indium tin oxide (ITO) electrode was used as a platform for
the immobilization of BiOBr on its surface. Thioglycolic acid
(TGA) was then used for the modification of the BiOBr modified
ITO electrode through dropping of its aqueous solution on the
surface and drying under an infrared lamp. Next, Ag2S was
grown in situ on the surface of the ITO/BiOBr/TGA electrode
via the addition of a solution mixture of the AgNO3 and Na2S.
After washing, dopamine (DA) was added to the electrode to
form a PD film. PD has very high adhesivity to biomolecules,
enabling efficient attachment of the anti-insulin antibody onto
the surface of the ITO/BiOBr/TGA/Ag2S/PD electrode. BSA was
finally dropped onto the electrode at room temperature to block
the nonspecific binding sites and make the device ready for
insulin detection. In this study, a high and stable photocurrent
signal was obtained by adding the excellent antioxidant ascorbic
acid (AA) to the sample being tested. Holes generated by the
illuminated Ag2S NPs oxidize AA, facilitating the separation of
photogenerated holes and electrons (h+/e) to achieve perfect
photoelectrochemical activity and photocurrent response.463 The
separation of photogenerated h+/e is inefficient under visible
light due to the wide band-gap of BiOBr, and therefore, Ag2S NPs
are used to promote electron transition under visible light
(Fig. 24b). The presence of PD also enhances the visible light
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absorption of BiOBr/Ag2S. The specific binding between insulin
present in the samples and the anti-insulin antibody present in
the electrode resulted in a linear decrease in the photocurrent
intensity with an increase in the amount of insulin in the sample.
The composite PEC sensor of BiOBr/Ag2S revealed its facile
preparation, high sensitivity (detection limit of 0.2 pg mL1),
reproducibility and perfect stability. A similar concept was also
proposed to detect squamous cell carcinoma antigens (SCCAs)
using a novel PEC immunosensor based on a BiOBr/Bi2S3
composite.464 Bi2S3 NPs were synthesized on BiOBr microstruc-
tures via a facile reaction between hydrothermally synthesized
BiOBr and S2 ions. Similar to the previous example, this
composite showed favorable PEC activity when AA was used
as an electron donor; however, its photocurrent intensity
was ca. 30 times higher than that of pure BiOBr, resulting in
the ultrasensitive determination of SCCA (Fig. 24c). Both of the
above examples used BiOBr because of its excellent photo-
electric activity, high chemical stability, and wide band gap
that can inhibit the recombination of electron–holes (e/h+)
and strengthen the photoelectric activity.465–467 Nevertheless,
the latter carries the benefits of the high valence band (VB) and
conduction band (CB) of Bi2S3, which subsequently accelerate
electron transfer under visible light irradiation and improves
the conductivities of the PEC biosensors. It is worth pointing
out that while BiOBr-based PEC detection of tetracycline, H2O2,
glucose, AA, and ciprofloxacin have been recently reported,468–470 the
use of BiOx for biosensing is still in its infancy and there is a long
way to go and much novel exploration for researchers to fabricate
highly sensitive sensors for use in biomedical applications.
8.2. Bi2Se3 for biosensing
As a three-dimensional topological insulator (TI), Bi2Se3 has
shown advantageous properties for biosensing, because of its
photothermal conversion ability,471 thermoelectric behavior,472
Dirac plasmons (oscillations of electrons)473 and distinctive
electrical conductivity (n-type conductivity, with an energy band
gap of 220 meV)474 that result from the existence of a single-
surface Dirac cone and a six-valley degeneracy in its structure.475
Strong spin–orbit coupling of Bi2Se3 induces nontrivial surface
states, which are completely protected against any time reversal
Fig. 24 (a) A schematic demonstration of the fabrication process of a BiOBr/Ag2S PEC immunosensor. Ag2S NPs were successfully grown in situ on the
surface of TGA modified BiOBr microspheres. (b) The electron-transfer mechanism of a PEC-based BiOBr/Ag2S immunosensor in PBS electrolyte
containing AA. (c) The photocurrent response curves of the PEC-based BiOBr/Ag2S immunosensor for the determination of insulin at various
concentrations. Adapted and reprinted with permission from ref. 457, Copyright 2017.
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perturbations, such as nonmagnetic impurities476 and crystal
defects. In addition, Bi2Se3 possesses electrochemical catalytic
properties,477 yielding a highly effective platform for the fabri-
cation of electrochemical biosensors with reduced background
signal and increased reproducibility through the suppression
of the fluctuation of the spin-polarized charge that is carried on
the surface states.478,479
Since rapid and selective detection of hydrogen peroxide
(H2O2) is in high demand, as it is an important biomarker of
the major reactive oxygen species associated with biological
disorders, Mohammadniaei et al.480 developed an electro-
chemical biosensor for its detection based on Bi2Se3 NPs
sandwiched between a gold electrode and a thin layer of
thermally-evaporated Au (Bi2Se3@Au). Fig. 25 shows that the
encapsulation by the Au thin layer kept the Bi2Se3 surface
protected, preventing its dissolution into the electrolyte,
improving its electrochemical-signal stability, and allowing
metallic DNA (mDNA) to be immobilized onto the substrate
through Au–thiol interactions and the formation of Bi2Se3@
Au–mDNA. The presence of mDNA, consisting of optimized
eight-Ag+-inserted dsDNA, rendered a discrete electrochemical
signal as a result of the H2O2 reduction due to the reversible
conversion of Ag2+ to Ag+, while Bi2Se3 acted as an electro-
chemical signal booster. As a result of the sharp redox signals
of the Ag+ ion and the low difference between the anodic and
cathodic peak potentials (DEp) of 66 mV that resulted in a high
electron-transfer rate across the structures, as well as increased
charge mobility between the interface by the Bi2Se3 NPs, a fast
current response was observed. The developed biosensor showed
a remarkable performance to discriminate between MCF-7 and
MDA-MB-231 breast cancer subtypes through the ultrafast
measurement (1.6 s) of H2O2 generation produced by each cell
line upon exposure to phorbol 12-myristate 13-acetate (PMA) and
with a very low detection limit of 10 109 M.480 Fan et al.25 also
Fig. 25 (a) A TEM image of Bi2Se3 NPs and their elemental mapping images obtained from energy-dispersive X-ray spectroscopy (EDS) analysis of the
NPs. (b–d) A schematic illustration of the fabrication process of the Bi2Se3@Au–mDNA electrode, and its electrochemical behavior for the detection of
H2O2 released from cancer cells. (e) Experimental results from H2O2 detection via the typical amperometric response recorded at a Bi2Se3@Au–mDNA
biosensor after the addition of 10 mL of a solution of PMA-induced MDA-MB-231 (violate), PMA-induced MCF-7 (blue), and PMA-induced medium (red).
The comparison of the Bi2Se3@Au–mDNA electrode with a Pierce kit demonstrates the reliable measurement of H2O2 using the developed Bi based
biosensor. Adapted and reprinted with permission from ref. 480, Copyright 2018.
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used Bi2Se3 NPs to fabricate an electrochemical hemoglobin (Hb)
biosensor by immobilizing Hb on the surface of Bi2Se3 NPs,
promoting the direct electron transfer of Hb, while retaining
its biological activity and high catalytic activity for the
reduction of H2O2.
8.3. Biosensors based on Bi2S3 NPs
Bi2S3 is another important type of n-type semiconducting
chalcogenide material, recently proposed for the development of
biosensors.481,482 Bi2S3 presents a broad absorption overlapping
with the near-IR and visible regions along with a tunable band
gap of between 1.3 and 1.7 eV, which gives it the benefit of being
able to absorb visible light over a wide wavelength range.483
Therefore, Bi2S3 can act as a light-harvesting substrate for the
development of PEC biosensors due to its high absorption
coefficient and high incident photon-to-electron conversion
efficiency.483,484 Nanotubes,485 nanorods,444,486,487 and nano-
sheets of Bi2S3,
488 as well as Bi2S3@MoS2 nanoflowers
489 are
examples of developed photoactive PEC nanosensors for the
detection of various analytes, such as methylated DNA,444
microRNA,489 amyloid-b proteins,487 avian leucosis virus490 and
sulfadimethoxine.491,492 For the avian leucosis virus (ALVs-J), for
example, Sun et al.490 used Bi2S3 nanorods as a photosensitive layer
on top of an ITO electrode to construct an immunosandwich-based
biosensor for the PEC detection of this virus. The electrode was
constructed by coating an ITO slice with Bi2S3 nanorods, followed
by a chitosan coating, attachment of an ALVs-J capturing antibody
on the chitosan layer, and finally BSA based surface blocking to
avoid unspecific binding. Samples containing increasing concen-
trations of ALVs-J were exposed to the electrode, upon which a
detection antibody conjugated to the surface of gold NPs was added
to form an immunosandwich complex with the viruses captured
on the surface of the antibody modified electrode. Alkaline
phosphatase (ALP) was conjugated on the surface of the AuNPs
to catalyze the hydrolysis of AAP to AA in situ for the donation of
electrons, which enhances the photocurrent of the biosensor.
The fabricated biosensor demonstrated a detection limit of 102.08
tissue culture infective dose 50 (TCID50).
One way to improve the sensing of Bi-based electrodes is to
combine BiNPs with other nanomaterials to form nanocompo-
sites. In recent work, Wang et al.493 introduced an innovative
enzyme-based PEC biosensor based on a dual signal quenching
strategy via the new concept of AA oxidase (AAO)–AA bioevent-
based electron donor consumption coupled with the steric
hindrance of silicon dioxide (SiO2) for the detection of carcino-
embryonic antigen (CEA). Ternary hybrid Bi2S3/Ag2S/TiO2 nano-
tube (NT) arrays were prepared and used as a photoelectrode, as
shown in Fig. 26a1. When the AuNPs were decorated on the
electrode array, the photocurrent was boosted significantly
due to the surface plasmon resonance of the AuNPs. After
the conjugation of an aptamer (Apt)–SiO2–AAO, the PEC
signal obviously decreased due to the dual quenching effect
originating from the enzymatic reaction between AAO and AA
that hampers the exposure of the surface of the electrode to the
AA and also the steric hindrance of the SiO2. In the presence of
CEA, the PEC response was remarkably increased owing to the
competition between the CEA and SH-DNA in binding to the
Apt of Apt–SiO2–AAO, resulting in the separation of some of
the Apt–SiO2–AAO and increased PEC signal due to the
reduced quenching effect. This study also revealed that ternary
Bi2S3/Ag2S/TiO2 NTs have better PEC performance compared
to TiO2 NTs only or binary Ag2S/TiO2 NTs and Bi2S3/TiO2 NTs
(Fig. 26a2). As a result of their wide band gap, TiO2 NTs possess
very poor photoelectric conversion efficiency, which results in a
low photocurrent response. Assembly of Ag2S on TiO2 causes a
tiny change in the PEC response, but the growth of Bi2S3 on the
Ag2S/TiO2 NTs resulted in a great increase in the photocurrent
intensity. This observation was ascribed to the facile transfer of
photogenerated electrons from the conduction band (CB) of
Bi2S3 to the CB of Ag2S and then to the CB of TiO2, consequently
promoting the effective separation of electron–hole pairs and
photocurrent enhancement. In the future, such novel concepts
can be expanded to achieve promising photoactive biosensors,
which can meet the challenging questions in the field of PEC-
based biochemical analysis for the detection of other proteins.
While there are plenty of materials with appropriate
electrical conductivity, there are major disadvantages that
hinder their wide usage in biosensing. For example, conductive
polymers like polyaniline (PANI) suffer from inferior electro-
chemical stability, weak resistance to acidity variation and poor
mechanical properties.494,495 To circumvent these weaknesses,
Bi2S3 NPs can be used to form composites that can make new
strides as active materials in the development of biomedical
sensors. Zhu et al.496 fabricated novel PANI–Bi2S3 nanocompo-
site through the potentiodynamic deposition of an ionic liquid-
carbon paste electrode (IL-CPE) modified with Bi2S3 nanorods in
an aniline solution (Fig. 26b1–b3), suggested as an immobiliza-
tion platform for oligonucleotides to develop impedimetric DNA
biosensors for the electrochemical detection of biomolecules. As
shown in Fig. 26b4, protonated aniline monomers first adsorb
onto the surface of the nanorods via an electrostatic interaction
between NH3
+ and S2 and coordination of NH2 with Bi
3+.
Electrochemical scanning then initiates the polymerization
reaction of the aniline molecules and Bi2S3 contributes to the
polymerization of aniline as an excellent electron transfer agent.
The results showed that negatively charged DNA probes tightly
adsorbed onto the surface of the modified electrodes while
maintaining their hybridization activity and identifying potential
target DNA with a detection limit of 4.37  1016 M. Excellent
electrical conductivity, large surface area, facile fabrication,
reproducibility, high stability, and good biocompatibility were
the main advantages of the devolved biosensor.
8.4. Bi nanocrystals and Bi film electrodes (BiFEs) for
biosensing
In addition to the abovementioned Bi-based nanomaterials, Bi
by itself can also form semimetal nanocrystals with distinctive
properties, such as large Fermi wavelengths, high magneto-
resistance and strong diamagnetism.497 As a result of its small
effective carrier mass, a semimetal-to-semiconductor transition
is expected in nanocrystal forms of Bi,498,499 a property which is
rarely applied in the fabrication of biosensors. Recently, Liu et al.456
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developed a novel core–shell nanohybrid (NH), in which Bi
nanocrystals were encapsulated within a heteroatom N,O-
codoped nanocarbon (NOC) ultrathin carbon shell (Bi@NOC)
as a PEC aptasensor for the early clinical diagnosis of cancer via
the detection of telomerase activity in cells (Fig. 27a). The core–
shell NHwas obtained by the reduction of Bi(Ac)3 in the presence
of oleylamine to generate Bi nanocrystal cores that can catalyze
the carbonization of folic acid to form NOC on the surface of the
core. Bi nanocrystals are recognized as a semiconductor with a
small band gap and unique potential to generate weak photo-
current upon excitation by visible light.500 While the NOC shell
endows the system with high compatibility as it is derived from
folic acid, it can also boost the interfacial electron transfer rate
and inhibit the electron–hole recombination in the Bi nanocrys-
tal core, because of its high charge carrier mobility and super
electron accepting ability.501 The combination of all these
criteria leads to the enhanced photoelectric conversion efficiency
and photocurrent intensity of the biosensor. In addition,
the Fermi level alignment of the core and the shell favorably
accelerate the generation of a photocurrent through the separa-
tion of photogenerated charge carriers, endowing the Bi@NOC
aptasensor with excellent PEC activity under the irradiation of
visible light. Thioflavin-T (Th-T), a fluorescent dye capable of
binding to telomere sequences in a G-quadruplex manner,502
was added to the biosensor as a telomerase-recognizing photo-
active reagent. AA was also used as an electron donor. The
Bi@NOC biosensor linearly and reproducibly detected telomerase
activity with a high sensitivity and low detection limit of only
60 cells.456 Although there are not a plethora of studies on
nanocrystalline Bi biosensors, the abovementioned features
demonstrate their potential application in the diagnosis of
clinically relevant pathologies, such as cancer.
Fig. 26 (a1) A schematic illustration of PEC-based CEA detection using a Bi2S3/Ag2S/TiO2 platform. Insert 1: a diagram showing the energy band levels of
the Bi2S3/Ag2S/TiO2 composite and the possible electron transfer process among the energy bands. Insert 2: dehydroascorbic acid (DHA) is produced
through the catalytic effect of AAO on AA oxidation. Insert 3: the localized surface plasmon resonance of AuNPs. (a2) PEC signals obtained with (1) TiO2
NTs, (2) Ag2S/TiO2 NTs, (3) Bi2S3/TiO2 NTs and (4) Bi2S3/Ag2S/TiO2 NTs. Adapted and reprinted with permission from ref. 493, Copyright 2018.
(b1) A schematic illustration of the electrochemical preparation of a PANI–Bi2S3 nanocomposite on IL-CPE and its application in an impedimetric DNA
biosensor. (b2 and b3) SEM images of the synthesized Bi2S3 nanorods and PANI coated Bi2S3 nanorods. The diameter of the nanorods increased from
210 to 450 nm after nanocomposite formation, confirming the uniform surface decoration of the Bi2S3 nanorods with PANI. (b4) A schematic
representation of PANI growth on Bi2S3 via electropolymerization. Adapted and reprinted with permission from ref. 496, Copyright 2015.
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The electrical, optical and structural characteristics of Bi
have also made it desirable to fabricate BiFEs for biosensing.503
Strategies for designing BiFEs include: electrochemical deposition
of Bi precursors;504,505 stripping voltammetry where a soluble Bi3+
salt is added to a sample solution and co-deposited with a target
analyte;506 and the incorporation of insoluble forms of Bi (Bi2O3
or BiPO4) into an ink for screen-printed electrode manufacturing
further associated with electrochemical deposition for the for-
mation of a thin film on the electrode surface.507 BiEF electrode
configurations are usually made by in situ and ex situ reduction of
Bi3+ ions and their subsequent deposition on the surface of
electrode substrates to form a film at nanoscale.508,509 Compared
to carbon and mercury film electrodes, BiFEs are economically
viable, can be deposited in various types of substrates, generally
possess high mechanical stability, are biocompatible and
environmentally friendly. The ability to form alloys with differ-
ent metals, simple preparation, well defined signals and partial
insensitivity to dissolved oxygen are also other benefits of BiFEs,
similar to those of mercury film electrodes.510 Bi compounds have
been used to modify different carbonaceous electrode materials,
such as carbon pastes,511 graphite-epoxy composites,512 boron-
doped diamond,513 carbon films,514 glassy carbon,431 screen-
printed carbon inks,515 or pencil graphite.516 Bi has also been
deposited in combination with polymers,517,518 and on metallic
electrodes, such as Au, Cu, or Pb.449
Studies have shown that the incorporation of Bi NPs onto an
electrode surface is more attractive compared to pre-plating the
BiFEs on the electrode.519,520 This is due to the fact that the
sensor characteristics, such as the sensitivity and detection
limit of the BiNP modified electrodes, are superior to those
of the BiFEs.521,522 In addition, BiNPs also showed superior
properties compared to those of BiFE, such as better biocom-
patibility, electrocatalytic activity, good conductivity, and larger
active surface area coupled with an enhanced mass transfer
effect, properties that generally improve the sensitivity and
detection limit of biosensors. For example, Nigovic et al.521
modified the surface of a glassy carbon electrode (GCE) with a
nanocomposite combination of BiNPs and carbon nanotubes
(CNTs) to form a BiNP–CNT/GCE sensor for the quantification
of the drug sulfasalazine in human serum samples. This sensor
indicated superior electroanalytical performance for drug deter-
mination in comparison to BiFE. However, BiFE also presented
advantages over the BiNP–CNT nanocomposite, such as its favor-
able surface stability and the possibility of performing successive
voltammetric measurements without time-consuming surface
cleaning, while the nanocomposite required the renewal of the
electrode surface after each experiment to achieve reproducible
measurements.521,522 In general, BiNPs are more attractive for
use in biosensing technology; however, the abovementioned
advantages of BiFEs have resulted in their usage in a wide range
Fig. 27 (a1) The schematically depicted fabrication process of the sensor for the telomerase detection via the PEC activity of Bi@NOC NH and the
telomerase-related signal amplification effect of Th-T. MEA is an abbreviation of monoethanolamine. (a2 and a3) TEM images of the obtained Bi@NOC
nanostructure at low (top) and high (bottom) magnification. The shell is shown between the red lines. (a4) The photocurrent intensity of the Bi@NOC NH
biosensor in response to increasing concentrations of cells from (a) 5  102 to (j) 1  106 cells per mL. Adapted and reprinted with permission from
ref. 456, Copyright 2018. The sequence of steps for the fabrication of (b1) an electrodeposited Bi WE sensor and (b2) an evaporated Bi WE sensor. (b3) A
close-up of the completed electrochemical sensor cell. Adapted and reprinted with permission from ref. 524, Copyright 2013.
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of interesting environmental and clinical applications, such as
trace metal detection431 and for the detection and measurement
of different compounds, such as aminosalycilate drugs,522
progesterone,510 glucose,523 zinc524 and vitamin B2.525 As a result
of the limitations of the bed-side monitoring of zinc (Zn) in
biological samples due to the requirement of expensive instru-
ments and expert personnel, Kang et al.524 reported the fabrica-
tion of a lab-on-a-chip BiFE sensor for detection using square
wave anodic stripping voltammetry. As shown in Fig. 27b, the
biosensor is composed of a Bi working electrode (WE), an
integrated silver/silver chloride (Ag/AgCl) reference electrode
(RE), and a gold auxiliary electrode (AE). The detection limit of
the sensor in 0.1 M of acetate buffer at pH 6 was 60 nM, with
rapid response, high accuracy at low concentrations of Zn, the
requirement of only a small sample volume, and reduced cost
among the main advantages of the developed sensor. The
electrodeposited Bi WE and evaporated Bi WE were fabricated
using two different protocols. For the electrodeposited Bi WE, a
single evaporation step was applied to deposit a gold metal layer,
and then, single photolithography patterning and electrode-
position of Bi were performed (Fig. 27b1). As for the evaporated
Bi WE process, the final device was achieved by: (1) deposition of
the gold metal layer via an evaporation step; (2) first photolitho-
graphy patterning to define the shape of the electrode; (3) second
photolithography step to define the sacrificial resist mask; (4) an
e-beam evaporation step to deposit a thin film of Bi; and
(5) finally, a lift-off step to pattern the Bi WE (Fig. 27b2). Using
the lab-on-a-chip BiFE sensor shown in Fig. 27b3, Zn was
successfully detected in serum samples by complementary
atomic absorption spectroscopy, demonstrating the potential
for the future development of portable BiFE-based biosensors
for the detection of biological analytes.
In this section, we discussed the most relevant properties
and described some of the latest advancements verified
throughout the last years in the application of Bi in biosensing
technology. Significant development has been achieved at a fast
pace in biosensing using Bi, allowing the replacement of
toxic metals, such as mercury in sensing devices, and direct
measurements in physiologically relevant samples or fluids. We
believe that in the future, BiNP-based biosensors may take up a
relevant position in the field of biosensing, as the advantages
of their use largely outweigh the drawbacks. Therefore, we
envisage that the present fast-paced development of Bi-based
biosensors will bring considerable significance to biomedical
applications in the near future.
9. Bi-Based biomaterials for tissue
engineering and implantation
Tissue engineering can be described as the capability to design
spatial and temporal structures to engender a favorable, biologically
inspired environment for scaffold matrices to fill tissue voids by cell
adhesion,migration, proliferation, and differentiation.526 The advent
of this interdisciplinary field has evolved towards the innovative
design and fabrication of biomaterials with stringent requirements,
to closely mimic the hierarchical constructs of native tissues for
regeneration and self-repair.527 The synergistic combination of
tissue engineering and regenerative medicine has been at the
forefront in recent years, as a result of the fabrication of three-
dimensional (3D) porous architectures with excellent biocompat-
ibility, controlled biodegradation and proper structures that
maintain oxygen and nutritional perfusion.528 Current efforts
have resulted in the introduction of new biomaterials for the
regeneration of different tissues, such as skin,529 bone,530,531
and cartilage.532 Bi is one of the new materials used to devise
promising new platforms for biocompatible scaffolding in the
field of tissue engineering and regenerative medicine.285,533
Therefore, there are very few reports on this application of Bi.
Thus, in this section, we will reflect on the emerging advance-
ments of this relatively new area of research and discuss the
considerations for further progress on Bi-containing formula-
tions concerning regenerative medical applications.
Bone is a complex type of tissue consisting of cells and
hierarchically arranged collagen fibrils, hydroxyapatite and proteo-
glycans aligned together as a hard structure with very high compres-
sive strength. While bone possesses considerable ability to repair
and renew itself, the regeneration process is not quick enough and it
is limited in severe bone defects.534–537 Harvesting bone autografts to
replace large bone defects is a common practice in medicine. Yet,
this may lead to a significant risk of morbidity, scarring and
deformity, as well as surgical complications, including bleeding,
inflammation and infection.538 This has encouraged new practices
in generating novel therapeutic formulations for bone tissue, provid-
ing an alternative to conventional implants.539,540 Bi has been
exploited as a new component to be included in bone scaffolds and
cements due to its favorable properties, such as biocompatibility,
low toxicity and environmentally friendly and stable photothermal
effects, advantageous in the therapeutic functionality of a materials-
based formulation for bone regeneration.541 In addition, when used
as a dopant in bioactive glass (BG), it can enhance the mechanical,
biological, and osteogenic properties of the BG.542 Radiopacity of
the Bi also facilitates imaging of the treated area using X-rays and
CT scanning.541,543 For example, bismuth aluminate (Al3BiO6) has
been used to increase opacity in calcium phosphate cements, at the
same time improving the proliferation of bone marrow stem
cells, demonstrating suitability for peri-/post-operative radiographic
assessment of cement placement after bone repair procedures and
possibly bone regeneration.541,544 BiNPs have also recently served
as active materials for bone tissue engineering. According to
Webster et al.,545 Bi3+ ions in the replacement of Ca2+ ions in
substituted hydroxyapatite, presented better alkaline phosphate
activity deposition of calcium-containing mineral, suggesting
enhanced osteoblast proliferation, pertinent for both bone
and dental applications. As a dopant, Bi improved osteoblast
long-term calcium-containing mineral deposition, adhesion,
and differentiation, therefore suggesting it to be a great dopant
choice for enhancing the properties of HA, leading to a revision
of the criteria essential for successful bone prosthetic
applications.
BGs have a wide range of clinical applications for the repara-
tion and reconstruction of bone, thus have been a preferential
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biomaterial for modification with Bi composites.543,546,547 BGs
have the ability to serve as an eluting agent of relevant ther-
apeutics, contributing to therapeutic strategies against diseases
such as osteomyelitis and bone cancer,543,548–551 particularly
when combined with Bi as one the main components. Regarding
the treatment of osteomyelitis, BGs by which the addition of Bi
ions renders them with antimicrobial activity and promoted
bone regeneration were investigated by Prasad et al.546 They
demonstrated a combinatorial antibacterial effect and cell pro-
liferation induction due to the combined action of antibacterial
Bi3+ ions and an increase in the pH value of the surrounding
medium caused by the BG.552 As for bone cancer-related defects,
Wang et al.543 described a photothermal effect in a Bi-doped
germanate BG, which demonstrated a dual function of hyper-
thermia (to kill lingering bone tumor cells) and bioactive proper-
ties for apatite remineralization and tissue repair, allowing
the treatment of large bone defects arising from bone tumor
therapy. The main mechanisms of action rely on a high photo-
thermal conversion efficiency that allows the effective killing of
bone tumor cells upon illumination with NIR light (by inducing
thermal apoptosis through heat generated from optical input),
as well as its ability to promote osteogenic cell adhesion,
proliferation, differentiation, and mineralization. Both in vitro
and in vivo data demonstrated promising results, regarding the
efficiency of the photothermal treatment in decreasing UMR106
bone tumor cells and tumor volume.543 Amultiferroic Bi-reinforced
BG was also recently developed by Khatua et al.196,553 in order to
investigate whether BiFeO3 in the BG can accelerate cellular
activities for rapid tissue healing by applying a magnetic field
externally to induce in situ electrical polarization. Mouse pre-
osteoblast cells on BG composites under different external
magnetic field treatments demonstrated 3-fold enhancement
of cell viability and proliferation for these composites at specific
magnetic field strengths of 200 or 350 milliTesla (mT), which
improved polarization and decreased the degree of crystalline
phases of the BG.196 These studies are considered to have
opened the door for the further investigation of the application
of Bi composites in bone repair.
Dental repair is another area of interest in which to use
Bi-based materials. The loss of dental tissue function due to
trauma, infection, abnormalities or congenital diseases is a
common health care problem worldwide.554 Owing to the
limited regenerative ability of hard teeth, the demand for a
novel therapeutic concept is required to provide an alternative
for dental transplantation and implantation. Despite the
relatively high success rate of implantation techniques, several
factors contribute to their shortcomings, as the need for
surgery, very costly nature of the procedures, as well as risk of
complications. Novel dental tissue regeneration studies aim to
enable cell-to-cell and cell-to-scaffold interactions at the micro
level through interconnected pores of scaffolds with adequate
mechanical properties and specific surface characterization
suitable for dental growth.555,556 An ideal filling material for
tooth repair is required to offer complete and impervious
obturation of the root canal system, sealing the pathways of
communication from their surrounding tissues.557 Similar to
their promising application in bone repair, Bi-based materials,
especially Bi2O3, have shown adequate biocompatibility, cell
proliferation and a three-dimensional structure adequate for
dental fillings. In addition, they present ideal radiopacity,
which is crucial for monitoring various stages of root canal
therapy and to enable easy monitoring of the filling of the root
canal with endodontic cement.544,558 For example, Kuratate
et al.533 investigated the reparative process of mechanically
exposed pulps treated and capped with MTA. MTA is a cement
composed of CaO, SiO, and Bi2O3, known to stimulate the
proliferation of fibroblasts and osteoblast-like cells. MTA can also
induce the gene expression of hard tissue-related proteins, such
as osteopontin, osteonectin, and osteocalcin in vitro. Treatment
with MTA demonstrated high frequency of dentin bridge for-
mation, occurring within 14 days after MTA capping in rat
molars.559–562 Bi2O3 was the main component of the MTA that
provided its radiopacity. In this study, the capacity of MTA to
induce regeneration of hard tissue in dental pulps was demon-
strated with proliferation, migration, and differentiation of pro-
genitor cells into new odontoblast-like cells before new matrix
secretion at the exposure site. Evidence of the cell proliferation,
the appearance of nestin-immunoreactive odontoblast-like cells,
and deposition of osteopontin, a noncollagenous protein involved
in matrix mineralization, were verified as potential signs of
dental regeneration. Similarly, to develop an ideal biomaterial
for orthopedic and dental tissues, Pazarçeviren et al.547 prepared
a Bi-doped nanobioactive bioglass (nBG) using a sol–gel method
and then made a composite by adding graphene oxide (GO). The
presence of Bi resulted in improved biocompatibility, increased
diametral tensile strength, and efficient cell spreading on the
composite. In the above studies, the role of Bi on the reparative/
regenerative processes was not studied in detail, but rather the
composites as a whole. Therefore, further studies are required in
order to understand the real role of Bi in the processes of dental
repair and/or regeneration.
These few examples of bone and dental repair by Bi-based
biomaterials demonstrate the infancy of the field and very early
stages of the investigation on the characterization and in vitro
assessment of such Bi-based composites, where the specific role
of the Bi component is not specifically or thoroughly understood
in the context of cellular repair. We believe that tissue engineering
research is slowly developing in this direction, which will be
fulfilled with more detailed studies in the coming years.
10. Conclusions and future
perspectives
Although in the last few years the research has increasing
on BiNPs due to their unique multifunctional potential for
different biomedical applications, there are still several challenges
that hinder their clinical translation, which require further inves-
tigations tomeet these challenges. One big challenge is the lack of
standard protocols to test and compare the biocompatibility of
these NPs prepared via different approaches. Different researchers
have tested BiNPs, but factors, such as the preparation method,
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functionalization method, particle size, particle charge, com-
position, shape, surface coating, applied dose, animal model,
type of model disease, etc., were different with no standard
reference for comparison. For example, Bi2O3 NPs demon-
strated different in vitro cytotoxicity behavior when annealed in
Ar and air.563 The air-annealed Bi2O3 NPs generated higher levels
of ROS, resulting in higher cell apoptosis and death, while the
Ar-annealed ones demonstrated a ROS-scavenging effect. There-
fore, it is presumed that the toxicity of BiNPs is dependent on the
preparation method, which subsequently affect their particle
size and surface chemistry. Therefore, a comprehensive study
is needed to establish correlations between the properties of
BiNPs, the experimental parameters, and their toxicity in order
to reliably discuss the biosafety of these particles. In addition,
genotoxicity studies and investigation of the apoptotic pathways
affected by BiNPs should be performed in the future for further
clarification of the toxicity of BiNPs.
Several studies have demonstrated both the biocompatibility of
BiNPs and also their rapid biodegradation in vivo,48,213,222,237,245,259
but most of these studies were based on short-term assays,
which cannot be expanded to determine the long-term bio-
safety of BiNPs. Overall, in order to classify BiNPs as ‘‘practi-
cally nontoxic’’ materials, a series of systematic biosafety
investigations on both small (e.g., zebra fish and mice) and
large animal models (e.g., pigs, dogs, and monkeys) are critical
for understanding their acute toxicity on various biosystems
(e.g., neurotoxicity, immunotoxicity, etc.) and chronic/long-term
side effects on different organs. Further information that is
missing is the behavior of BiNPs at the nano-biointerface,
where cellular mechanisms involved in the uptake of BiNPs
into various types of cells should be studied. The determination
of precise mechanisms will allow the development of favorable
NPs for efficient therapeutic purposes. Further surface modifi-
cation of BiNPs with various materials and their effects on
immunogenicity, pharmacokinetics, and biodistribution of the
particles is another area that is not well explored.
As for the fabrication process of BiNPs, most of the current
approaches are based on bottom-up synthesis and efforts have
still not shifted to top-down methods. Hence, more attempts
should be devoted in this area to explore morphology
and surface termination controllable top-down procedures.
Additionally, the marriage of BiNPs with other functional
materials should be investigated further to fabricate hybrid
nanostructures that combine the advantages of both for multi-
functional biomedical applications. The fabrication of ultra-
small Bi-based quantum dots and their usage in biomedicine
also needs further attention.564–566 Similar to other types of
quantum dots, the attractive luminescence properties of Bi
quantum dots can be applied in diagnostic medicine. Never-
theless, the synthesis of these ultra-small particles is quite
challenging. One strategy, which is worth testing, might be
through the filtration of big particles after sequential rounds
of centrifugation. Moreover, further novel studies on Bi nano-
composites with the capability of responding to both NIR-I
(700–950 nm) and NIR-II (1000–1700 nm) windows is beneficial
for deep-tissue applications and would direct the design of
BiNPs with enhanced PTT efficiency. This property will also
allow the design of novel theranostics through the PAI and PTT
of deep tissues.
Tuning of the optical and electrical properties of BiNPs via
the doping of various elements on their surface or alteration of
surface termination is another area of exploration to create
highly sensitive Bi-based biosensors. It is noted that while the
development of BiNPs in nanomedicine is still in its infancy,
emerging trends are expected to shift from the current focus
on antibacterial therapeutics or cancer therapy toward the
exploitations of their potential in the design of wearable, as well
as lab-on-a-chip biosensors with desirable multifunctionality,
programmability and biocompatibility. This specific application
of BiNPs is achievable by designing multicomponent composites
and developing ground-breaking fabrication strategies. The
catalytic properties of BiNPs have recently attracted attention
in biosensing, because of their possible function in catalyzing
specific biological reactions. The exploration of new scenarios in
this field is a research hotspot, which needs further clarification
in the future studies on BiNPs. In addition, the potential benefits
of BiNPs should be further explored for stem-cell engineering
through thermo-modulation, gene therapy, active targeting of
different organs within the body rather than just cancer cells,
regenerative medicine, development of novel hydrogel based
3D-cell cultures, containing BiNPs for thermal or electrical
signaling of the encapsulated cells, preparation of injectable
thermoresponsive hydrogels, and thermally or electrically
induced re-programming of immune cells (see the detailed
perspectives in Fig. 28).
This review has distinctly shown the great optimism
surrounding the use of BiNPs and their composites as promising
platforms for use in different biological and biomedical applica-
tions. Bi-based nanomaterials can be engineered with numerous
functionalities to achieve specific physical, chemical, and bio-
logical properties. The unrivalled advantage of BiNPs is their
high versatility, recognized as reproducible nanostructures,
which can be applied in diagnostic multi-imaging, as sensitizer
for PTT and RT, antibacterial agents, biosensing, and also as
tissue regenerative materials. Moreover, compared to many
other types of metal-based NPs, the challenges of BiNPs seems
to be less in terms of the translation of applications, due to
their precise composition/structure control, facile large-scale
production, and ease of surface engineering. The low price of
BiNPs also adds double value to their other abovementioned
benefits and is considered as a very strong driving force for
further studies on the scale-up of new Bi-based nanomedicines.
Nevertheless, comprehensive and long-term monitoring of their
biosafety must be taken into account before BiNPs themselves
can flourish as important materials in biomedicine. To do this,
we should be aware of the fact that the implementation of
toxicity assays by following existing guidelines is compulsory.
This is suggested as we expect the continued expansion of
research on BiNPs at a rapid rate and the emergence of their
novel biomedical applications in the near future.
In summary, the ongoing research progress in the field of
BiNPs can lead to exceptional advances in current therapeutic
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methods for cancer by affecting the biology of diseased tissues
beyond our imagination. It is our opinion that while highly
detailed and time-consuming investigations are needed to
move products into the clinical trial phase, BiNPs might cross
this path in a fast manner and commercialized products could
enter the market in the near future. It is highly expected that
multidisciplinary efforts among biologists, chemists, physi-
cists, and engineers will promote a mechanistic understanding
of BiNPs and allow the limitations of Bi-based nanomedicines
to be pushed, while moving the currently successful paradigms
more rapidly toward clinical translation.
List of abbreviations
AAO Ascorbic acid oxidase
AE Auxiliary electrode
AIPH 2,2-Azobis[2-(2-imidazolin-2-
yl)propane]dihydrochloride
Al3BiO6 Bismuth aluminate
ALP Alkaline phosphatase
ALT Alanine aminotransferase
ALVs-J Avian leucosis virus
AOT Bis(2-ethylhexyl)sulfosuccinate
APS Ammonium persulfate
APTMS (3-Aminopropyl) trimethoxysilane
Ar Argon
ASTM American Society for Testing and Materials
Au Gold
AuNPs Gold nanoparticles
Ba Barium
BACP-2 Bi-asparagine coordination polymer spheres
BAL 2,3-Dimercapto-1-propanol
BC Bismuth citrate
BET Brunauer–Emmett–Teller
BG Bioactive glass
Bi Bismuth
BiNPs Bismuth-containing nanoparticles
Bi(NO3)35H2O Bismuth nitrate pentahydrate
Bi(OH)3 Bismuth hydroxide
(Bi2O)2CO3 Bismuth oxide carbonate
Bi@Co@CN) NPs Nitrogen-rich carbon-coated bismuth/cobalt
Bi2MoO6 Bismuth molybdate
Bi2O3 Bismuth oxide
Bi2S3 Bismuth sulfide
Bi2Se3 Bismuth selenide
Bi2Te3 Bismuth telluride
Bi2WO6 Bismuth tungstate
BiCl3 Bismuth chloride
BiFeO3 Bismuth ferrite
BiFEs Bi film electrodes
BiOBr Bismuth oxybromide
Fig. 28 A summary of the current research developments, conclusions, and future perspectives related to BiNPs and Bi-containing composites for
versatile biomedical applications.
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